FPCG First Physicians Capital Group Inc (CE)

 

 

FORM 10-K

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

(MARK ONE)

þ		ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Fiscal Year Ended September 30, 2010

OR

o		TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Transition Period from                      to                     

Commission file number: 000-30326

FIRST PHYSICIANS CAPITAL GROUP, INC.

(Exact name of Registrant as Specified in its Charter)

DELAWARE		77-0557617
(State or Other Jurisdiction		(I.R.S. Employer
of Incorporation or Organization)		Identification No.)
433 North Camden Drive #810
Beverly Hills, California		90210
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code:
(310) 860-2501

SECURITIES REGISTERED PURSUANT TO SECTION 12 (b) OF THE ACT: NONE

SECURITIES REGISTERED PURSUANT TO SECTION 12 (g) OF THE ACT:
COMMON STOCK, PAR VALUE $0.01 PER SHARE

Indicate by check mark whether the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. o Yes þ No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. o Yes þ No

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. þ Yes o No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit and post such files). o Yes þ No

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer o		Accelerated filer o		Non-accelerated filer o		Smaller reporting company þ
				(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). o Yes þ No

The aggregate market value of common stock of the registrant held by non-affiliates of the registrant on March 31, 2010 was $7,486,777, computed upon the basis of the closing price on that date.

Number of shares of common stock outstanding as of January 31, 2011			15,049,507

 

 

FIRST PHYSICIANS CAPITAL GROUP, INC.
FORM 10-K ANNUAL REPORT
FOR THE PERIOD ENDED SEPTEMBER 30, 2010

TABLE OF CONTENTS

		Page
PART I			3
Item 1. BUSINESS			3
Item 1A. RISK FACTORS			11
Item 2. PROPERTIES			18
Item 3. LEGAL PROCEEDINGS			19
Item 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS			19
PART II			19
Item 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER REPURCHASES OF EQUITY SECURITIES			19
Item 6. SELECTED CONSOLIDATED FINANCIAL DATA			22
Item 7. MANAGEMENT’S DISCUSSION & ANALYSIS OF RESULTS OF OPERATIONS			22
Item 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK			29
Item 8. CONSOLIDATED FINANCIAL STATEMENTS			30
Item 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE			55
Item 9A(T). CONTROLS AND PROCEDURES			56
Item 9B. OTHER INFORMATION			56
PART III			56
Item 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT			56
Item 11. EXECUTIVE COMPENSATION			59
Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS			67
Item 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS			70
Item 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES			71
PART IV			72
Item 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES			72
SIGNATURES			79
EXHIBIT INDEX			80
Subsidiaries
Certification Pursuant to Rule 13a-14(d)
Certification Pursuant to Rule 13a-14(d)
Certification Pursuant to 18 U.S.C. 1350
Certification Pursuant to 18 U.S.C. 1350

SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS

The discussion in this Form 10-K (this “ Form 10-K ”) for the fiscal year ended September 30, 2010 (the “ Fiscal Year Ended September 30, 2010 ”) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “ Securities Act ”), Section 21E of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), and, if applicable, the Private Securities Litigation Reform Act of 1995, including, among others, (i) prospective business opportunities and (ii) our potential strategies for redirecting and financing our business. Forward-looking statements are statements other than historical information or statements of current condition. Some forward-looking statements may be identified by use of terms such as “believes,” “anticipates,” “intends” or “expects.” These forward-looking statements relate to our plans, objectives and expectations. Although we believe that our expectations with respect to the forward-looking statements are based upon reasonable assumptions within the bounds of our knowledge of our business and operations, in light of the risks and uncertainties inherent in all future projections, the inclusion of forward-looking statements in this report should not be regarded as a representation by us or any other person that our objectives or plans will be achieved. Readers should carefully review the risk factors described in this document as well as in our other documents that we file from time to time with the Securities and Exchange Commission (“ SEC ”), including our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.

We undertake no obligation to release publicly the results of any future revisions we may make to forward-looking statements to reflect events or circumstances after the date of this report or to reflect the occurrence of unanticipated events.

PART I

Item 1.		BUSINESS

References to “we,” “us,” “our,” “TIGroup,” “FPCG” or the “Company” refers to First Physicians Capital Group, Inc. (f/k/a Tri-Isthmus Group, Inc.) and its subsidiaries. We maintain our executive offices at 433 North Camden Drive, #810, Beverly Hills, California 90210. Our telephone number is +1 (310) 860-2501, and our website is at www.firstphysicianscapitalgroup.com .

In November 2007, our Board of Directors approved a change to our fiscal year end from January 31 to September 30. In view of this change, we filed a Transition Report on Form 10-KT for the eight-month period ended September 30, 2007 (the “ Transition Period Ended September 30, 2007 ”) on January 15, 2008. A Form 10-KT/A amendment to that report was filed on February 11, 2008. Since that time, we filed a Form 10-K for each of the fiscal years ended September 30, 2008 (the “ Fiscal Year Ended September 30, 2008 ”) and September 30, 2009 (the “Fiscal Year Ended September 30, 2009”) on January 12, 2009 and January 12, 2010 respectively. This Form 10-K report covers the twelve-month period ended September 30, 2010 and the twelve-month period ended September 30, 2009, with additional information on other fiscal years, as required by SEC rules and regulations.

Information in this Form 10-K is current as of January 31, 2011 unless otherwise specified.

COMPANY BACKGROUND

We were originally incorporated in Nevada in October 1980 and re-incorporated in Delaware in November 2000. From 2001 to November 2004, we provided Fortune 500 and Global 500 companies with customizable and comprehensive business process outsourcing (“ BPO ”) solutions into and across the Asia-Pacific region. In November 2004, our active business operations ceased with the sale of our BPO operations in Asia.

On December 16, 2005, at our Annual Meeting of Stockholders, our stockholders voted to amend our Certificate of Incorporation to change our legal name from “Vsource, Inc.” to “Tri-Isthmus Group, Inc.” (“ TIGroup ”) and to reduce the number of authorized shares of our common stock, par value $0.01 per share (the “ Common Stock ”), from 500,000,000 shares to 100,000,000 shares, as described in our Definitive Proxy Statement filed with the SEC on November 28, 2005. The reduction of the number of authorized shares of our Common Stock did not affect the number of shares of Common Stock issued and outstanding.

During the Fiscal Year Ended January 31, 2007 (the “ Fiscal Year Ended January 31, 2007 ”), we resumed active operations following the acquisition of two ambulatory surgical centers located in Southern California. On December 2, 2005, through newly created indirect subsidiaries, we entered into two separate purchase agreements to acquire from Surgical Ventures, Inc., a California corporation, a controlling interest in two separate outpatient surgical centers in San Diego, California, Point Loma Surgical Center, L.P. and Outpatient Surgery of Del Mar, L.P. and we completed these acquisitions on November 16, 2006. On February 9, 2007, we converted these limited partnerships into Outpatient Surgery of Point Loma, L.L.C. (“ Point Loma ”) and Outpatient Surgery of Del Mar, L.L.C. (“ Del Mar ,”) and, together with Point Loma, the (“ San Diego ambulatory surgical centers ”), respectively. In June 2007, we consolidated the operations of the San Diego ambulatory surgical centers at the Del Mar facility.

On October 29, 2007, we acquired 51% of the issued and outstanding membership units of Rural Hospital Acquisition, LLC, an Oklahoma limited liability company (“ RHA ”). Based in Oklahoma City, RHA owns and operates three critical access hospitals, one medical clinic and an ancillary support services unit, all focused on the delivery of healthcare services to rural communities in Oklahoma. On May 1, 2008, RHA Anadarko, LLC, a wholly owned subsidiary of RHA, purchased 100% of the issued and outstanding membership interests of Southern Plains Medical Center (“ SPMC ”). Founded in 1915, SPMC is one of the oldest continuously operating multi-specialty physician practices in the United States. Located in Chickasha, Oklahoma, SPMC’s 15 physicians and other licensed healthcare providers deliver primary and specialty care in the following areas: family medicine; pediatrics; internal medicine; acute care; occ/med; general surgery; gynecology; ophthalmology; orthopedic surgery; radiology; oncology; cardiology and urology. Ancillary services provided onsite include imaging (computer-assisted tomography (“ CT ”), magnetic resonance imaging (“ MRI ”), mammography, x-ray, EKG, vascular and ultra-sound bone densitometry) and laboratory services. SPMC also provides urgent care services outside of normal business hours seven days a week through its “Quick Care” department. Beginning November 18, 2008, RHA began operating under the trade name Southern Plains Medical Group. On December 11, 2008, we acquired the remaining 49% of the issued and outstanding membership units of RHA, making RHA an indirect wholly-owned subsidiary of ours.

On December 12, 2008, we and certain of our subsidiaries entered into three loan agreements, effective November 6, 2008, with two Oklahoma-based lenders, Canadian State Bank and Valliance Bank, resulting in an aggregate debt financing of $8.4 million. We obtained the financing to purchase the building and real property of the Stroud Regional Medical Center Hospital and clinics, refinance existing loans totaling $4.6 million, upgrade facilities at the Johnston Memorial Hospital and improve the consolidated balance sheet and maintain general working capital. The loans are evidenced by promissory notes issued by RHA Anadarko, LLC, RHA Stroud, LLC and RHA Tishomingo, LLC, two of which mature on November 6, 2028 and one of which matures on November 6, 2024.

On May 1, 2009, we purchased The Chandler Clinic (“ TCC ”), a family medical practice located in Chandler, Oklahoma. TCC is located within the service area of the Stroud Regional Medical Center.

On September 29, 2009, at our Annual Meeting of Stockholders, our stockholders voted to amend our Certificate of Incorporation to change our legal name from “Tri-Isthmus Group, Inc.” to “First Physicians Capital Group, Inc.” to reflect our focus on the healthcare industry. We became First Physicians Capital Group, Inc. on September 29, 2009.

CURRENT OPERATIONS

Following the sale of our BPO operations in November 2004, we reduced our headcount significantly to a two-person staff when David Hirschhorn and Todd Parker joined us as our Co-Chief Executive Officers in July 2005. Our new management initiated a growth strategy defined by acquisitions. Our management team and Board of Directors have been and are currently comprised of a group of individuals with complementary talents across a broad range of disciplines, including mergers and acquisitions, finance and operations.

During the Fiscal Years Ended January 31, 2006 and January 31, 2007, our management team focused our acquisition strategy on the healthcare industry.

In December 2006, we resumed active operations following the acquisition of the San Diego ambulatory surgical centers.

In 2007, we refined our acquisition strategy to focus on the delivery of financial and managerial services to healthcare facilities in non-urban markets.

In September 2007, David Hirschhorn became our sole Chief Executive Officer upon Todd Parker’s resignation. Dennis M. Smith, formerly a director and senior consultant to us, re-joined us as our Chief Financial Officer. On October 9, 2008, Mr. Smith’s employment agreement with us was terminated. Effective January 26, 2009, Mr. Smith ceased to be our Chief Financial Officer. Upon the termination of his employment agreement, Mr. Smith had certain contractual rights, pursuant to which we continued to pay Mr. Smith until April 9, 2009. Mr. Smith was offered a severance package to continue his pay beyond April 9, 2009 in recognition for past services rendered, and Mr. Smith accepted the severance package which entitled him to severance payments which began May 10, 2009 and lasted until October 20, 2009. Mr. Smith had and has no disagreements with us on any matter related to our operations, policies or practices. On March 3, 2009, Mr. Smith resigned as a member of our Board of Directors.

In November 2008, we appointed Thomas Rice as President of RHA. Mr. Rice has over 37 years’ experience in the administration and operation of healthcare facilities, including key senior management positions with major Oklahoma-based healthcare services companies. Also in November 2008, we announced the addition of Donald C. Parkerson as Chief Financial Officer of RHA, a position he held until June 2009 when he ceased acting as the CFO of RHA. On January 30, 2009, Mr. Parkerson was also appointed as our Chief Financial Officer. Mr. Parkerson has served in financial leadership positions with companies in healthcare businesses during his more than 30-year career. In November 2008, we hired Richard Rentsch as Vice President of Finance of RHA, and currently he serves as the Chief Accounting Officer of RHA. Mr. Rentsch is an experienced financial leader with more than 25 years of healthcare experience.

Our support staff at RHA’s hospitals and Del Mar consists of registered nurses, operating room technicians, an administrator who supervises the day-to-day activities of the surgery center and a small number of office staff. Each operating unit also has appointed a medical director, who is responsible for and supervises the quality of medical care provided at the center. Use of our surgery centers is limited to licensed physicians. With the acquisition of SPMC in May 2008, we added 15 physicians and other healthcare providers to our team at RHA as employees. Our business depends upon the efforts and success of these physicians and non-employee physicians who provide medical services at our facilities. Our business could be adversely affected by the loss of our relationship with, or a reduction in use of our facilities by, a key physician or group of physicians.

As discussed above, in December 2008, RHA became an indirect wholly-owned subsidiary of ours with the acquisition by RHA of the interests not already held by us.

On January 13, 2010, Southern Plains Medical Center, Inc., our wholly-owned indirect subsidiary and an Oklahoma corporation (“ SPMC ”), entered into a sale/leaseback transaction pursuant to a purchase agreement, whereby SPMC sold certain property to Southern Plains Associates, LLC (“SPA”). SPA is an Oklahoma limited liability company, in which our wholly-owned subsidiary, First Physicians Realty Group, LLC, an Oklahoma limited liability company owns 50% and Capital Investors of Oklahoma, LLC, an Oklahoma limited liability company own the other 50%.

The purchase price for the sale/leaseback transaction was paid to SPMC as follows: (i) $1,500,000 was paid in the form of a promissory note, dated January 13, 2010, and (ii) $4,500,000 was paid in cash at the closing. Our wholly-owned subsidiary, First Physicians Realty Group, LLC, an Oklahoma limited liability company, owns 50% of SPA, and Capital Investors of Oklahoma, LLC, an Oklahoma limited liability company, owns 50% of SPA.

In connection with the purchase agreement, SPMC leased back from SPA the property sold, pursuant to a lease agreement dated December 16, 2009. The lease agreement provides for a 20-year term with an automatic 10-year renewal.

The $4,500,000 in cash proceeds was used to pay off short-term debt associated with the property sold in the amount of $3,700,942, plus related interest. SPMC received net proceeds of $732,221 after retirement of the debt and other associated closing costs. Restricted cash on deposit with the debt holder and pledged as a security on the debt in the amount of $1,524,091 was released and returned to us.

More detailed information regarding this transaction may be found in our Current Report on Form 8-K, which was filed with the SEC on January 20, 2010.

On June 14, 2010, Sean Kirrane was hired as our Vice President of Finance and Controller. Mr. Kirrane has over 10 years experience in senior finance and accounting roles for large publicly traded companies. On August 23, 2010, Mr. Kirrane was appointed to serve as the Company’s Principal Accounting Officer following Mr. Parkerson’s departure.

On August 23, 2010 Donald C. Parkerson resigned his position as Chief Financial Officer, effective this same date. Mr Parkerson’s employment with the Company was governed by an Executive Services Agreement, dated June 27, 2008, by and between the Company and Tatum LLC. Mr. Parkerson had no disagreements with us on any matter related to our operations, policies or practices.

Strategy

Our initial strategy was to identify and invest in “platform” companies in the business services and healthcare industries that provided essential core offerings, which could be expanded over time. As we focused our efforts in the healthcare industry, two particular segments, ambulatory surgical centers and rural hospitals, stood out in terms of potentially favorable economics, positive regulatory trends, inherent cost advantages, improving demographics and, for non-urban healthcare opportunities, a large, under-served market. We determined that the top-down trends and attractive cash flows of ambulatory surgical centers made this an area of particular interest. Less well-known, however, is the non-urban sector, which has suffered from a long-term lack of access to capital despite providing care to more than 50 million people in the United States. We determined that focusing on rural healthcare could represent a significant long-term opportunity for us.

On October 29, 2007, we acquired 51% of the issued and outstanding membership units of RHA. Based in Oklahoma City, RHA owns and operates three critical access hospitals, one medical clinic and an ancillary support services unit, all focused on the delivery of healthcare services to rural communities in Oklahoma. Together, the acquisition of RHA and the subsequent acquisition of SPMC by RHA are referred to herein collectively as the “ RHA Acquisition ,” and the three RHA hospitals, the medical clinic, ancillary support services units and SPMC are referred to herein collectively as the “ RHA Healthcare Operations .” On May 1, 2008, RHA purchased 100% of the issued and outstanding membership interests of SPMC. Beginning November 18, 2008, RHA began operating under the trade name “Southern Plains Medical Group.” On December 11, 2008, through one of our wholly-owned subsidiaries, we acquired the remaining 49% of the issued and outstanding membership units of RHA, making RHA an indirect wholly-owned subsidiary.

Our portfolio was expected to consist of (i) majority interests in healthcare platforms or facilities, such as RHA, the San Diego ambulatory surgical center and SPMC and (ii) equity positions in a diversified portfolio of minority interests in ambulatory surgical centers with a history of positive cash flows. In addition, we expect to selectively invest in business solutions providing financial and processing services to healthcare providers and physicians and in support of new treatment solutions.

In line with our strategy, we re-branded our activities. The operations in non-urban markets previously known as RHA were re-branded “Southern Plains Medical Group” to leverage the old and well-established recognition that SPMC has in the regional markets. In addition, effective September 29, 2009, we changed our name to “First Physicians Capital Group, Inc.” to reflect our focus on the healthcare industry.

In response to local market economic conditions including the expected impact of changes in healthcare law, during the Fiscal Year ended September 30, 2010 we have shifted our strategy and embarked upon initiatives to reorganize our operations. Our strategy has transitioned away from majority ownership in healthcare delivery companies to a focus on healthcare management services and the financing of equipment and real estate used by healthcare entities. We will maintain or acquire minority ownership in selected healthcare delivery companies that complement our management services and financing activities. We will also invest in, acquire or partner with other companies that provide similar services in our markets.

In pursuit of this reorganization, we are divesting underperforming facilities and reducing or outsourcing administrative functions to better align cost structures and business volume.

FUNDING

We have sustained operating losses and negative operating cash flow since our inception and had an accumulated deficit of approximately $95.5 million as of September 30, 2010, which has been funded primarily through the issuance of preferred stock and common stock, the issuance of promissory notes and cash generated from operations.

Our recurring losses from operations and anticipated future losses raises substantial doubt about our ability to continue as a going concern. Our plan of operations, even if successful, may not result in cash flow sufficient to finance our business. Realization of our assets is dependent upon our continued operations, which in turn is dependent upon meeting financing requirements and the success of future operations.

Our ability to continue as a going concern is dependent on improving profitability and cash flow and securing additional financing. While we believe in the viability of our strategy to raise additional funds and that the actions presently being taken provide the opportunity to continue as a going concern, there can be no assurances to that effect. Our financial statements do not include any adjustments related to the recoverability and classification of liabilities that might be necessary if we are unable to continue as a going concern.

As of September 30, 2010 we had current liabilities of $10.3 million and current assets of $6.5 million.

INTELLECTUAL PROPERTY

We formerly operated under the trademarks Tri-Isthmus Group™ and TIGroup™. In line with our strategy, we re-branded our activities. The operations in non-urban markets currently known as RHA were re-branded “Southern Plains Medical Group” to leverage the old and well-established recognition that SPMC has in the regional markets in which we operate. In addition, effective September 29, 2009, we changed our name to “First Physicians Capital Group, Inc.” to reflect our focus on the healthcare industry.

We do not currently have any patents, trademarks, licenses, franchises, concessions, royalty agreements or labor contracts, other than those that are incidental and customary to our business, such as licenses to use software applications.

EMPLOYEES

We have four employees at the parent company level as of January 31, 2011, including David Hirschhorn, our chairman and Chief Executive Officer, Sean Kirrane, our Vice President of Finance and Controller, a director of corporate development and an administrative secretary. We consider our relations with employees to be good. None of our employees are represented by a labor union or work under any collective bargaining agreement.

As of January 31, 2011, RHA and Del Mar employed 160 and 26 personnel, respectively. The RHA employee count excludes those employed by RHA Tishomingo, LLC and The Chandler Clinic, LLC, both wholly-owned subsidiaries of RHA. As of January 6, 2011, we have divested the operations of RHA Tishomingo, LLC and The Chandler Clinic, LLC. See Item 8, Footnote No. 17, “Subsequent Events”, for further discussion of the sale of these operations. We consider relations with employees at each of RHA and Del Mar to be good. None of these employees are represented by a labor union or work under any collective bargaining agreement.

GOVERNMENT REGULATIONS

The United States healthcare industry is subject to extensive regulation by a number of governmental entities at the federal, state and local level. Government regulation affects our business activities by controlling our growth, requiring licensure and certification for our facilities, regulating the use of our properties and controlling reimbursement to us for the services we provide.

State Licensing and CONs

State licensing of ambulatory surgical centers, rural hospitals and surgical hospitals is generally a prerequisite to the operation of each center and to participation in federally-funded programs, such as Medicare and Medicaid. Once a facility becomes licensed and operational, it must continue to comply with federal, state and local licensing and certification requirements, as well as local building and safety codes. In addition, every state imposes licensing requirements on individual physicians and facilities, as well as services operated and owned by physicians. Physician practices are also subject to federal, state and local laws dealing with issues such as occupational safety, employment, medical leave, insurance regulations, civil rights and discrimination and medical waste and other environmental issues.

Certificate of Need (“ CON ”) statutes and regulations control the development of ambulatory surgical centers in certain states. CON statutes and regulations generally provide that, prior to the expansion of existing centers, the construction of new centers, the acquisition of major items of equipment or the introduction of certain new services, approval must be obtained from the designated state health planning agency. In giving approval, a designated state health planning agency must determine that a need exists for expanded or additional facilities or services. We do not operate in any CON states currently, but we may do so in the future.

Corporate Practice of Medicine

The laws of certain states in which we operate or may operate in the future do not permit business corporations to practice medicine, exercise control over physicians who practice medicine or engage in various business practices, such as fee-splitting with physicians. The interpretation and enforcement of these laws vary significantly from state to state. We are not required to obtain a license to practice medicine in any jurisdiction in which we currently own and operate ambulatory surgical centers, rural hospitals or surgical hospitals because these entities are not engaged in the practice of medicine as defined by state laws. The physicians who perform procedures at the ambulatory surgical centers, rural hospitals and surgical hospitals are individually licensed to practice medicine. In some instances, the physicians and physician group practices are not affiliated with us other than through the physicians’ ownership in the limited partnerships and limited liability companies that own the surgery centers and through the service agreements we have with some physicians. The laws in most states regarding the corporate practice of medicine have been subjected to limited judicial and regulatory interpretation. We cannot provide assurances that our activities, if challenged, will be found to be in compliance with these laws.

Certification

We depend on third-party programs, including governmental and private health insurance programs, to reimburse us for services rendered to patients in our facilities. In order to receive Medicare reimbursement, each facility must meet the applicable conditions of participation set forth by the United States Department of Health and Human Services, or DHS, relating to the type of facility, the services it provides, its equipment, personnel and standard of medical care, as well as compliance with state and local laws and regulations, all of which are subject to change from time to time. Ambulatory surgical centers and hospitals undergo periodic on-site Medicare certification surveys. Each of our existing facilities is certified as a Medicare provider. Although we intend for our facilities to participate in Medicare and other government reimbursement programs, there can be no assurance that these centers will continue to qualify for participation.

Medicare-Medicaid Fraud and Abuse Provisions

Section 1128B(b) of the Social Security Act (the “ Federal Anti-Kickback Statute ”) prohibits the knowing or willful offering, payment, solicitation or receipt or remuneration, directly or indirectly, overtly or covertly, in cash or in kind, for: (1) the referral of patients or arranging for the referral of patients to receive services for which payment may be made in whole or in part under a federal or state healthcare program; or (2) the purchase, lease, order or arranging for the purchase, lease or order of any good, facility, service or item for which payment may be made under a federal or state healthcare program. The Federal Anti-Kickback Statute is very broad in scope and many of its provisions have not been uniformly or definitively interpreted by case law or regulations. Violations may result in criminal penalties or fines of up to $25,000, imprisonment for up to five years, or both. Violations of the Federal Anti-Kickback Statute may also result in substantial civil penalties, including penalties of up to $50,000 for each violation, plus three times the amount claimed and exclusion from participation in the Medicare and Medicaid programs. Exclusion from these programs would result in significant reductions in revenue and would have a material adverse effect on our business.

As authorized by Congress, the Office of the Inspector General (“ OIG ”) promulgated safe harbor regulations that outline categories of activities protected from prosecution under the Federal Anti-Kickback Statute. These safe harbors cover, among other things, investment interests, personal services and management contracts and employment arrangements. Although conduct or business arrangements that do not fall within a safe harbor are not unlawful per se , noncompliant conduct or business arrangements risk increased scrutiny by governmental enforcement authorities.

In addition to the Federal Anti-Kickback Statute, the Health Insurance Portability and Accountability Act of 1996, or “ HIPAA, “ provides for criminal penalties for healthcare fraud offenses that apply to all health benefit programs, including the payment of inducements to Medicare and Medicaid beneficiaries in order to influence those beneficiaries to order or receive services from a particular provider or practitioner. Federal enforcement officials have numerous enforcement mechanisms to combat fraud and abuse, including the Medicare Integrity Program and an incentive program under which individuals can receive up to $1,000 for providing information on Medicare fraud and abuse that leads to the recovery of at least $100 of Medicare funds. In addition, federal enforcement officials have the ability to exclude from Medicare and Medicaid any investors, officers and managing employees associated with business entities that have committed healthcare fraud.

Evolving interpretations of current, or the adoption of new, federal or state laws or regulations could affect many of our arrangements. Law enforcement authorities, including the OIG, the courts and Congress, are increasing their scrutiny of arrangements between healthcare providers and potential referral sources to ensure that the arrangements are not designed as a mechanism to exchange remuneration for patient care referrals and opportunities. Investigators also have demonstrated a willingness to look behind the formalities of a business transaction to determine the underlying purposes of payments between healthcare providers and potential referral sources.

Prohibition on Physician Ownership of Healthcare Facilities and Certain Self-Referrals

Section 1877(a) of the Social Security Act sets forth the federal physician self-referral law, commonly referred to as the “Stark Law,” which prohibits a physician from making a referral for a designated health service to an entity if the physician or a member of the physician’s immediate family has a financial relationship with the entity, subject to certain exceptions. Sanctions for violating the Stark Law include civil money penalties of up to $15,000 per prohibited service provided and exclusion from the federal healthcare programs. The Stark Law applies to referrals involving the following services under the definition of “designated health services”: clinical laboratory services; physical therapy services; occupational therapy services; radiology and imaging services; radiation therapy services and supplies; durable medical equipment and supplies; parenteral and enteral nutrients, equipment and supplies; prosthetics, orthotics and prosthetic devices and supplies; home health services; outpatient prescription drugs and inpatient and outpatient hospital services.

The Center for Medicare and Medicaid Services (“ CMS ”) issued two phases of final regulations implementing the Stark Law, which became effective on January 4, 2002 and July 26, 2004, respectively. Most recently, on September 5, 2007, CMS issued the third phase of final regulations which became effective on December 4, 2007. While these regulations help clarify the requirements of the exceptions to the Stark Law, it is unclear how the government will interpret the exceptions for enforcement purposes.

Nevertheless, under these regulations, services that would otherwise constitute a designated health service, but that are paid by Medicare as a part of the surgery center payment rate, are not a designated health service for purposes of the Stark Law. In addition, the Stark Law contains an exception covering implants, prosthetics, implanted prosthetic devices and implanted durable medical equipment provided in a surgery center setting under certain circumstances. Therefore, we believe the Stark Law does not prohibit physician ownership or investment interests in our surgery centers to which they refer patients.

With regard to the rural hospitals and the surgical hospitals, the Stark Law regulations include exceptions for investments in rural providers and hospital ownership. We believe the investment structure of each of our rural hospitals and surgical hospitals complies with either the rural provider or hospital ownership exception.

The “rural provider” exception under the Stark Law reads as follows:

“The following ownership or investment interests in the following entities do not constitute a financial relationship: (1) A rural provider, in the case of DHS furnished in a rural area by the provider. A “rural provider” is an entity that furnishes substantially all (not less than 75 percent) of the DHS that it furnishes to residents of a rural area and, for the 18-month period beginning on December 8, 2003 (or such other period as Congress may specify), is not a specialty hospital. A rural area for purposes of this paragraph (c)(1) is an area that is not an urban area as defined in Sec. 412.62(f)(1)(ii) of this chapter.”

The “hospital ownership exception” under the Stark Law reads as follows:

“The following ownership or investment interests in the following entities do not constitute a financial relationship: A hospital that is located outside of Puerto Rico, in the case of DHS furnished by such a hospital, if:

(i) the referring physician is authorized to perform services at the hospital;

(ii) effective for the 18-month period beginning on December 8, 2003 (or such other period as Congress may specify), the hospital is not a specialty hospital; and

(iii) the ownership or investment interest is in the entire hospital and not merely in a distinct part or department of the hospital.”

In 2003, Congress passed legislation modifying the hospital ownership exception to the Stark Law by creating an 18-month moratorium on allowing physician ownership of new specialty hospitals. While the moratorium technically expired in 2005, the DHS suspended the processing of new provider enrollment applications for specialty hospitals, effectively extending the moratorium. On August 28, 2006, CMS issued its final report to Congress (the “ Final Report ”) addressing the specialty hospital moratorium as required by the Deficit Reduction Act of 2005. In the Final Report, CMS declined to extend the suspension of processing new provider enrollment applications for specialty hospitals. CMS also declined to recommend an amendment to the whole hospital exception to exclude physician investments in specialty hospitals. Nevertheless, future regulatory changes may prohibit physicians from investing in specialty hospitals. The Stark Law defines a “specialty hospital” as a hospital that primarily or exclusively treats cardiac, orthopedic or surgical conditions or any other specialized category of patients or cases designated by regulation. According to this definition, we believe that none of our facilities is a “specialty hospital,” and therefore, the moratorium does not apply to our facilities. There can be no assurance, however, that the federal government will not amend the definition of “specialty hospital” to include the any of our facilities.

Furthermore, on July 12, 2007, CMS published proposed updates to the Medicare Physician Fee Schedule for 2008, which included a number of significant proposed revisions to the Stark Law. While none of the proposed revisions are directly relevant for purposes of this disclosure, investors should be aware that CMS may propose changes to the Stark Law in the future that may significantly impact our investment structures and our relationships with referring physicians.

We also have various compensation arrangements, including personal service arrangements and management arrangements with physicians that we have structured to comply with applicable Stark Law exceptions.

The Federal False Claims Act and Similar Federal and State Laws

The False Claims Act (the “ FCA ”) prohibits any person from knowingly presenting or causing to be presented a false or fraudulent claim, record or statement to obtain payment from the government or decrease any payments owed to the government. Governmental enforcement agencies or courts may impose fines up to three times the actual damages sustained by the government, plus mandatory civil penalties of between $5,500 and $11,000 for each separate false claim.

Criminal false claims provisions apply to (1) false claims or statements made knowingly or willfully to obtain benefits under Medicare or Medicaid or feign compliance with certification requirements, or (2) failure to refund, knowingly and with fraudulent intent, Medicare and Medicaid funds not properly paid. Governmental enforcement agencies or courts may impose up to five years in prison, $25,000 in fines for each offense, or both.

FCA claims may be brought by governmental enforcement authorities or by individuals on the government’s behalf under the FCA’s qui tam , or “whistleblower,” provisions. Whistleblower provisions allow private individuals to bring actions on behalf of the government alleging that the defendant defrauded the federal government. Additionally, HIPAA established (1) civil liability for up-coding and billing medically unnecessary items and services, and (2) federal criminal sanctions for healthcare fraud against a private, nongovernmental healthcare benefit program. Although we have implemented policies and procedures to avoid violations of these laws, there can be no assurance that the conduct will not be reviewed and challenged by whistleblowers or governmental enforcement authorities. Any adverse determination could subject us to criminal and civil liability.

A number of states have adopted their own false claims provisions as well as their own qui tam provisions whereby a private party may file a civil lawsuit in state court. We are currently not aware of any actions against us under any such state laws.

Healthcare Industry Investigations

Both federal and state government agencies have heightened and coordinated civil and criminal enforcement efforts as part of numerous ongoing investigations of healthcare companies, as well as their executives and managers. These investigations relate to a wide variety of topics, including referral and billing practices.

From time to time, the OIG and the United States Department of Justice (the “ DOJ ”) have established national enforcement initiatives that focus on specific billing practices or other suspected areas of abuse. Some of our activities could become the subject of governmental investigations or inquiries. For example, we have significant Medicare billings and we have joint venture arrangements involving physician investors. In addition, our executives and managers, many of whom have worked at other healthcare companies that are or may become the subject of federal and state investigations and private litigation could be included in governmental investigations or named as defendants in private litigation. We are not aware of any governmental investigations involving any of our facilities, our executives or our managers. A future adverse investigation of us, our executives or our managers could result in significant expense to us, as well as adverse publicity.

Privacy Requirements and Administrative Simplification

Federal and state governmental enforcement authorities extensively regulate the confidentiality of patient health information. HIPAA privacy regulations regulate the use and disclosure of patient health information, whether communicated electronically, on paper or orally. The regulations also provide patients with significant rights related to understanding and controlling how their health information is used or disclosed. HIPAA security regulations require healthcare providers to implement administrative, physical and technical safeguards to protect the security of patient health information that is maintained or transmitted electronically. Further, as required by HIPAA, DHS has adopted regulations establishing electronic data transmission standards that all healthcare providers must use when submitting or receiving certain healthcare transactions electronically.

The penalty for failure to comply with HIPAA privacy and security standards is a fine of up to $100 for each violation, with a maximum penalty of $25,000 imposed for all violations of an identical requirement during a calendar year. Additionally, any person or entity who violates HIPAA privacy or security regulations may be fined up to $250,000, imprisoned for not more than 10 years or both. We believe we comply in all material respects with all applicable federal and state laws, rules and regulations governing the privacy and security of patient health information. Because of the complexity of these regulations, however, there can be no assurance that our privacy and security practices will not be reviewed and found not to be in compliance with these standards. An adverse determination by governmental enforcement authorities could materially and adversely affect our business.

In addition, our facilities will continue to remain subject to any state laws that are more restrictive than the HIPAA privacy and security regulations. These statutes vary by state and could impose additional penalties.

Environmental Regulation

Our operations generate medical waste that must be disposed of in compliance with federal, state and local environmental laws, rules and regulations. Our operations are also subject to compliance with various other environmental laws, rules and regulations. Such compliance costs are not significant, and we do not anticipate that they will be significant in the future.

Medicare and Medicaid Regulatory and Audit Impacts

Medicare and state Medicaid programs are subject to regulatory changes, administrative rulings, interpretations and determinations, post-payment audits, requirements for utilization review and new governmental funding restrictions, all of which could materially increase or decrease program payments, impact cost of providing services and affect the timing of payments to our hospitals. The final determination of amounts received under the Medicare and Medicaid programs often takes many years because of audits by the programs’ representatives, providers’ rights of appeal and the application of numerous technical reimbursement provisions. Until final adjustments are made, certain issues remain unresolved and established allowances may be higher or lower than what is ultimately required.

The Medicare program utilizes a system of contracted carriers and fiscal intermediaries across the country to process claims and conduct post-payment audits. Per the Medicare Prescription Drug, Improvement and Modernization Act of 2003 (the “ 2003 Act ”), CMS is reforming the carrier and fiscal intermediary functions. As part of such reform, CMS is competitively bidding the carrier and fiscal intermediary functions to Medicare Administrative Contractors. These changes could affect claims processing, auditing and cash flow to Medicare providers.

COMPETITORS

In our current markets, we compete with other healthcare providers, including major acute care, surgical, specialty and rural hospitals and other surgery centers. We compete with other providers for patients, physicians and for contracts with insurers or managed care payors. There are several publicly-held companies, or divisions of large publicly-held companies, that acquire and develop freestanding multi-specialty surgery centers. Some of these competitors have greater resources than we do. The principal competitive factors that affect our ability and the ability of our competitors to acquire surgery centers and private surgical, rural and specialty hospitals are price, experience, reputation and access to capital. The principal competitive factors that affect our surgery centers are location and the quality of medical care provided by our physician-partners and other physicians who use our facilities.

Item 1A.		RISK FACTORS

ANY INVESTMENT IN OUR COMMON STOCK INVOLVES A HIGH DEGREE OF RISK. YOU SHOULD CAREFULLY CONSIDER THE FOLLOWING RISK FACTORS IN ADDITION TO THE OTHER INFORMATION CONTAINED IN THIS REPORT.

Risks Related to Our Business

We have a need for ongoing financing.

We will need additional capital to continue to maintain and expand our operations and will endeavor to raise funds through the sale of equity shares and other types of securities and revenues from operations. There can be no assurance that we will generate revenues from operations or obtain sufficient capital on acceptable terms, if at all. Failure to obtain such capital or generate such operating revenues would have an adverse impact on our financial position and results of operations and ability to continue as a going concern. Our operating capital and capital expenditure requirements during the fiscal year ending September 30, 2011 and thereafter will vary based on a number of factors, including the level of sales and marketing activities for our services and products.

Our recurring losses from operations and anticipated future losses raise substantial doubt about our ability to continue as a going concern. Our plan of operations, even if successful, may not result in cash flow sufficient to finance our business. Realization of our assets is dependent upon our continued operations, which in turn is dependent upon meeting financing requirements and the success of future operations.

Our ability to continue as a going concern is dependent on improving profitability and cash flow and securing additional financing. While we believe in the viability of our strategy to raise additional funds and that the actions presently being taken provide the opportunity to continue as a going concern, there can be no assurances to that effect.

There can be no assurance that additional private or public financings, including debt or equity financing, will be available as needed, or, if available, on terms favorable to us. Any additional equity financing may be dilutive to stockholders and such additional equity securities may have rights, preferences or privileges that are senior to those of our existing Common Stock. Furthermore, debt financing, if available, will require payment of interest and may involve restrictive covenants that could impose limitations on our operating flexibility. Our failure to successfully obtain additional future funding may jeopardize our ability to continue our business and operations. If we raise additional funds by issuing equity securities, existing stockholders may experience a dilution in their ownership. In addition, as a condition to giving additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders.

We are subject to uncertainties regarding healthcare reform.

The Patient Protection and Affordable Care Act (the “PPACA”), passed by Congress and signed into law in March 2010, has created uncertainty related to our ability to grow and pursue profitable healthcare services. The PPACA has provisions with phased implementation starting in 2010 and continuing through 2014. Among the PPACA provisions are price controls and incentives placed on doctors and hospitals, insurance market reforms to increase the availability of health insurance, requirements that all individuals obtain health insurance coverage or pay a tax and the creation of government health insurance exchanges for small businesses and individuals Since Congressional approval of the PPACA, several states have passed legislation challenging the constitutionality of the legislation. We cannot predict which healthcare reforms will be adopted and, if adopted how such reforms could harm our business. It is possible that these reforms may be interpreted and applied in a manner that is inconsistent with our business practices. If so, in addition to the possibility of fines, this could result in an order requiring that we change our business practices, which could have an adverse effect on our business. Complying with these various reforms could cause us to incur substantial costs or require us to change our business practices in a manner adverse to our business.

The recent disruption in the overall economy and the financial markets may adversely impact our business.

Many industries, including businesses providing healthcare solutions outside of traditional hospital settings, have been affected by current economic factors, including the deterioration of national, regional and local economic conditions, declines in employment levels and shifts in consumer spending patterns. The recent disruptions in the overall economy and volatility in the financial markets have reduced, and may continue to reduce, consumer confidence in the economy, negatively affecting consumer spending, which could be harmful to our financial position. Disruptions in the overall economy may also lead to a lower collection rate on billings as consumers or businesses are unable to pay their bills in a timely fashion. Decreased cash flow generated from our businesses may adversely affect our financial position and our ability to fund our operations. In addition, macroeconomic disruptions, as well as the restructuring of various commercial and investment banking organizations, could adversely affect our ability to access the credit markets. The disruption in the credit markets may also adversely affect the availability of financing for our acquisition of interests in ambulatory surgical centers, rural hospitals, surgical hospitals and other healthcare delivery platforms. There can be no assurance that government responses to the disruptions in the financial markets will restore consumer confidence, stabilize the markets or increase liquidity and the availability of credit.

We are dependent for our success on a few key executive officers. Were we to lose one or more of these key executive officers, we would be forced to expend significant time and money in the pursuit of a replacement, which would result in both a delay in the implementation of our business plan and the diversion of working capital.

Our success depends to a critical extent on the continued efforts and services of our Chief Executive Officer, David Hirschhorn and our Vice President of Finance and Controller, Sean Kirrane. Were we to lose one or more of these key executive officers, we would be forced to expend significant time and money in the pursuit of a replacement or replacements, which would result in both a delay in the implementation of our business plan and the diversion of limited working capital. We can give you no assurance that we can find satisfactory replacements for these key executive officers at all, or on terms that are not unduly expensive or burdensome to us. Although Mr. Hirschhorn has signed an employment agreement with us, his agreement does not preclude him from leaving us, nor can we assure you that the noncompetition provisions contained in his employment agreement would be enforceable in any such event.

Our ability to retain or attract employees that provide healthcare services may be adversely impacted by recent changes in employee benefit programs.

Our success depends to a critical extent on the healthcare services provided by our current and future employees. The recent removal of certain employee benefit programs in response to escalating health care costs may result in the loss of current employees and the inability to recruit future employees. In this event, we would be forced to expend significant time and money in the pursuit of satisfactory replacements. We can give you no assurance that we can find satisfactory replacements for these employees, or on terms that are not unduly expensive or burdensome to us.

If we are unable to acquire and develop additional healthcare facilities on favorable terms, we may be unable to execute our acquisition and development strategy, which could limit our future growth.

Part of our strategy to increase our revenues and earnings is through the continuing acquisition of interests in hospitals, physician practices, ambulatory surgical centers, surgical hospitals and other healthcare delivery platforms operating in partnership with physicians’. Our efforts to execute our acquisition and development strategy may be affected by our ability to identify suitable candidates and negotiate and close acquisition and development transactions. We are currently evaluating potential acquisitions and development projects and expect to continue to evaluate acquisitions and development projects in the foreseeable future. The businesses we acquire may experience losses in their early months of operation, or may never become profitable. We may not be successful in acquiring additional companies or achieving satisfactory operating results at acquired or newly developed facilities. Further, the companies or assets we acquire in the future may not ultimately produce returns that justify our related investment. If we are unable to execute our acquisition and development strategy, our ability to increase revenues and earnings through future growth would be impaired.

We have incurred significant losses and may incur losses in the future.

We have sustained operating losses since inception and had an accumulated deficit of approximately $95.7 million as of September 30, 2010. This deficit has been funded primarily through sales of equity, the issuance of promissory notes and cash generated from operations. Our management intends to continue in the pursuit of a growth strategy defined by acquisitions. We anticipate that our operating expenses will increase in the foreseeable future as we increase our acquisition activities, and continue to develop our technology, products and services. We will need to generate significant revenues to achieve profitability, and we cannot assure you that we will ever realize revenues at such levels. If we do achieve profitability in any period, we may not be able to sustain or increase our profitability on a quarterly or annual basis.

If we incur material liabilities as a result of acquiring companies, hospitals or ambulatory surgical centers, our operating results could be adversely affected.

Although we conduct extensive due diligence prior to the acquisition of companies, hospitals, ambulatory surgical centers, physician practices and other healthcare businesses, and seek indemnification from prospective sellers covering unknown or contingent liabilities, we may acquire companies that have material liabilities for failure to comply with healthcare laws and regulations or other past activities. Although we maintain professional and general liability insurance, we do not currently maintain insurance specifically covering any unknown or contingent liabilities that may have occurred prior to any acquisition. If we incur these liabilities and are not adequately indemnified or insured for them, our operating results and financial condition could be adversely affected.

If we are unable to manage growth, we may be unable to achieve our growth strategy.

We expect to continue to expand our operations in the future. To accommodate our past and anticipated future growth, and to compete effectively, we will need to continue to implement and improve our management, operational and financial information systems and to expand, train, manage and motivate our workforce. Our personnel, systems, procedures or controls may not be adequate to support our operations in the future. Further, focusing our financial resources and management attention on the expansion of our operations may negatively impact our financial results. Any failure to implement and improve our management, operational and financial information systems, or to expand, train, manage or motivate our workforce, could reduce or prevent our growth.

If we rely on third parties to provide services that are critical to our operations, we may have reduced financial and operational control which may result in a material impact on our ability to operate.

In the future, we expect to utilize third parties to provide outsourced business functions. The reduced financial and operational control over third parties poses an additional risk over having direct control over these functions.

If we are unable to grow revenues at our existing facilities, our operating margins and profitability could be adversely affected.

Our growth strategy includes increasing our revenues and earnings by increasing the number of procedures performed at our facilities. Because we expect the amount of the payments we receive from third-party payors to remain fairly consistent, our operating margins will be adversely affected if we do not increase the revenues and procedure volume of our facilities to offset increases in our operating costs. We seek to increase procedure volume and revenues at our surgical facilities by increasing the number of physicians performing procedures at our centers, obtaining new or more favorable managed care contracts, improving patient flow at our centers, promoting screening programs, increasing patient and physician awareness of our facilities and achieving operating efficiencies. We can give you no assurances that we will be successful at increasing or maintaining revenues and operating margins at our facilities.

Appropriate acquisitions or investment opportunities may not be available.

As noted above, we may use a portion of our cash resources to pursue acquisition opportunities. If we decide to seek such opportunities, our future results will be dependent on our ability to identify, attract and complete desirable acquisition opportunities, which may take considerable time. In addition, our cash position, $1.7 million at September 30, 2010, may limit the scale and therefore the number of opportunities available. Our future results will be dependent on the performance of the acquired businesses, if any. We may not be successful in identifying, attracting or acquiring desirable acquisition candidates, or in realizing profits from any acquisitions.

With the completion of the acquisition of the San Diego ambulatory surgical centers, our strategy evolved during the Fiscal Year Ended January 31, 2007 from a focus on investment in “platform” strategies in the business services and healthcare industries to a concentration on healthcare and ancillary services, targeting companies valued at $3 million to $50 million. In particular, we are actively seeking to build our portfolio of interests in healthcare services operations, including ambulatory surgical centers, rural hospitals, surgical hospitals and other healthcare delivery platforms operating in partnership with physicians. Our strategy is predicated on management’s belief that the provision of flexible financial solutions to ambulatory surgical centers, specialty hospitals and other healthcare platforms aligns our interests with those of physician-partners, providing the basis for interdependent relationships that should establish sound operating partnerships and deliver solid risk adjusted returns. Our portfolio is expected to consist of (i) majority interests in healthcare platforms or facilities, such as RHA and the San Diego ambulatory surgical center and (ii) equity positions in a diversified portfolio of minority interests in ambulatory surgical centers with a history of positive cash flows. In addition, we will selectively invest in business solutions providing financial and processing services to healthcare providers and physicians and in support of new treatment solutions.

We will have sole and absolute discretion in identifying and selecting acquisition and investment opportunities and in structuring, negotiating and undertaking transactions with our target companies. We may acquire, invest or be sold (in whole or in part) at any time, as our Board of Directors and management determine is appropriate. Our stockholders generally will not be able to evaluate the merits of the acquisition, investment or sale (partial or otherwise) before we take any of these actions. In addition, in making decisions to complete acquisitions, investments or a sale, we will rely, in part, on financial projections developed by our management and financial advisors and the management of potential target companies. These projections will be based on assumptions and subjective judgments. The actual results of these transactions may differ significantly from these projections.

A significant portion of our revenues are produced by a small number of our facilities, which are concentrated in Oklahoma and California.

A significant portion of our revenues are produced by a small number of our facilities based in Oklahoma and California. Our future patient volumes, net revenues and profitability in this market could be unfavorably impacted as a result of increased competitor capacity and expansion of services. A continuation of increased provider competition in this market, as well as potential future capacity added by us and others, could result in additional erosion of the patient volumes, net revenues and financial operating results of our facilities in this market.

The significant portion of our revenues derived from these facilities makes us particularly sensitive to regulatory, economic, environmental and competition changes in Oklahoma and California. Any material change in the current payment programs or regulatory, economic, environmental or competitive conditions in these states could have a disproportionate effect on our overall business results.

We depend on our relationships with the physicians who use our facilities. Our ability to provide medical services at our facilities would be impaired and our revenues reduced if we were unable to maintain these relationships.

Our business depends upon the efforts and success of the physicians who provide medical and surgical services at our facilities and the strength of our relationships with these physicians. Our revenues would be reduced if we lost our relationship with one or more key physicians or group of physicians or if such physicians or groups reduce their use of our facilities. In addition, any failure of these physicians to maintain the quality of medical care provided or to otherwise adhere to professional guidelines at our surgical facilities, or any damage to the reputation of a key physician or group of physicians could damage our reputation, subject us to liability and significantly reduce our revenues.

Continued growth in the number of uninsured and underinsured patients or further deterioration in the collectability of the accounts of such patients could harm our results of operations.

The principal collection risks for our accounts receivable relate to uninsured patient accounts and patient accounts for which the primary insurance carrier has paid the amounts required by the applicable agreement but patient responsibility amounts (e.g., deductibles, co-payments and other amounts not covered by insurance) remain outstanding. If we continue to experience significant increases in uninsured and underinsured patients and/or uncollectible accounts receivable, our results of operations could be harmed.

We may incur liabilities not covered by our insurance or which exceed our insurance limits.

In the ordinary course of business, our subsidiary hospitals are subject to medical malpractice lawsuits, product liability lawsuits and other legal actions. Some of these actions may involve large claims, as well as significant defense costs. We self-insure a substantial portion of our liability risks for property and other typical insurance coverage with commercial carriers, subject to self-insurance retention levels. We believe that, based on our past experience and actuarial estimates, our insurance coverage and our self-insurance reserves are sufficient to cover claims arising from the operations of our subsidiary hospitals. However, if payments for claims and related expenses exceed our estimates or if payments are required to be made by us that are not covered by insurance, our business could be harmed and our results of operations could be adversely impacted. We believe that our insurance is adequate in amount and coverage. However, in the future, insurance may not be available at reasonable prices or we may have to increase our levels of self-insurance.

Because we have facilities in Oklahoma and California, we may incur liabilities or have operational difficulties as a result of damage from tornados, mudslides, earthquakes and wildfires, as well as damage from other natural disasters.

We own and operate hospitals in Oklahoma. Oklahoma has one of the highest rates of tornado activity in the United States. Potential tornado damage and disruption to our hospitals, as well as employees’ homes, local businesses, local infrastructure (such as roads and bridges leading to our hospitals) and physicians’ offices could be extensive. If we experience damage as a result of tornados or other natural disasters in the vicinity of any of our Oklahoma facilities, the results of operations could be harmed due to financial losses to repair or rebuild our facilities or disruption to our customers or employees that could negatively impact our operations.

We also own and operate facilities in California. Mudslides, earthquakes, wildfires and other natural disasters occur frequently in California. Potential damage and disruption in our facilities, local businesses, local infrastructure (such as roads and bridges leading to our hospitals) or employees’ homes located in California as a result of mudslides, earthquakes, wildfires or other natural disasters could be substantial. If we experience mudslides, earthquakes, wildfires or other natural disasters in the vicinity of any of our California facilities, our reputation and results of operations could be harmed due to financial losses to repair or rebuild our facilities or disruption to our customers or employees that could hurt our ability to effectively provide our services.

Risks Related to Our Industry/General Market Conditions

Current and future disruptions in the banking industries may limit our access to our funds or cause us to lose funds, which could negatively impact our business.

We are affected by certain economic factors that are beyond our control, including changes in the overall banking environment. Due to the current economic climate, some banks may fail. The rate of bank failures has increased significantly in recent periods. A large percentage of our cash is held in banks, not all of our cash is insured by the FDIC against an event of bank failure and it would be impractically burdensome to rearrange our banking relationships to ensure a 100% insurance coverage rate on our deposits. Should a bank at which we have a deposit fail, we could lose all funds that are not insured or face significant delays in recovering funds if any recovery of our uninsured amounts is possible at all. The loss of our cash, or the ability to access our cash, could have a material adverse affect on our business and could possibly cause us to file for bankruptcy or be forced to dissolve.

We depend on payments from third-party payors, including government healthcare programs. If these payments are reduced, our revenue will decrease.

We are dependent upon private and governmental third-party sources of payment for the services provided to patients in our facilities. The amount of payment a facility receives for its services may be adversely affected by market and cost factors as well as other factors over which we have no control, including Medicare and Medicaid regulations and the cost containment and utilization decisions of third-party payors. Fixed fee schedules, capitation payment arrangements, exclusion from participation in or inability to reach agreement with managed care programs or other factors affecting payments for healthcare services over which we have no control could also cause a reduction in our revenues.

If federal or state healthcare programs or managed care companies reduce the payments we receive as reimbursement for services we provide, our net operating revenues may decline.

In recent years, federal and state governments made significant changes in the Medicare and Medicaid programs, including the 2003 Act. Some of these changes could decrease the amount of money we receive for our services relating to these programs . In recent years, Congress and some state legislatures have introduced an increasing number of other proposals to make major changes in the healthcare system including an increased emphasis on the linkage between quality of care criteria and payment levels such as the submission of patient quality data to the Secretary of Health and Human Services. Federal funding for existing programs may not be approved in the future. Future federal and state legislation may further reduce the payments we receive for our services. In addition, insurance and managed care companies and other third parties from whom we receive payment for our services increasingly are attempting to control healthcare costs by requiring that hospitals discount payments for their services in exchange for exclusive or preferred participation in their benefit plans. We believe that this trend may continue and may reduce the payments we receive for our services, which will lead to a decrease in our revenues without a corresponding reduction in our costs.

Providers in the hospital industry have been the subject of federal and state investigations and we could become subject to such investigations in the future.

For the past several years, significant media and public attention has been focused on the hospital industry due to ongoing investigations related to referrals, cost reporting and billing practices, laboratory and home healthcare services and physician ownership of joint ventures involving hospitals. Both federal and state government agencies have previously announced heightened and coordinated civil and criminal enforcement efforts. Moreover, the OIG and the DOJ have, from time to time, established enforcement initiatives that focus on specific areas of suspected fraud and abuse. Recent initiatives included a focus on hospital billing practices.

In March 2005, CMS implemented a three-year pilot recovery audit contractor program, commonly known as “RAC,” covering providers in certain states where we operate hospitals. RAC auditors are independent contractors hired by CMS. Among other things, the auditors have been focusing on clinical documentation supporting billings under the Medicare program. If an auditor concludes that such documentation does not support the provider’s Medicare billings, CMS will revise the amount due to the provider, compare such amount to what was previously paid and withhold the difference from a current remittance. The affected facility can appeal the auditor’s decision through an administrative process. At the conclusion of the pilot demonstration program, a permanent program may be implemented that will include hospital providers throughout the country.

We closely monitor our billing and other hospital practices to maintain compliance with prevailing industry interpretations of applicable laws and regulations, and we believe that our practices are consistent with those in our industry. However, government investigations could be initiated that are inconsistent with industry practices and prevailing interpretations of existing laws and regulations. In public statements, government authorities have taken positions on issues for which little official interpretation had been previously available. Some of those positions appear to be inconsistent with practices that have been common within our industry and, in some cases, they have not yet been challenged. Moreover, some government investigations that were previously conducted under the civil provisions of federal law are now being conducted as criminal investigations under fraud and abuse laws.

We cannot predict whether we will be the subject of future governmental investigations or inquiries. Any determination that we have violated applicable laws or regulations or even a public announcement that we are being investigated for possible violations could harm our business by the issuance of injunctions requiring that we change our practices, loss of confidence by customers and damage to our reputation, fines and other losses. Becoming subject to such investigations could cause us to incur substantial costs or require us to change our business practices in a manner adverse to our business.

If we fail to comply with other applicable laws and regulations, we could suffer penalties or be required to make significant changes to our operations.

We are subject to many laws and regulations at the federal, state and local government levels in the jurisdictions in which we operate. These laws and regulations require that our healthcare facilities meet various licensing, certification and other requirements, including those relating to:

	•		physician ownership of our facilities;
	•		the adequacy of medical care, equipment, personnel, operating policies and procedures;
	•		building and safety codes;

	•		licensure, certification and accreditation;
	•		billing for services;
	•		maintenance and protection of records; and
	•		environmental protection.

We believe that we are in material compliance with applicable laws and regulations. However, if we fail or have failed to comply with applicable laws and regulations, we could suffer civil or criminal penalties, including the loss of our licenses to operate and our ability to participate in Medicare, Medicaid and other government-sponsored healthcare programs. New interpretations or enforcement of existing or new laws and regulations could subject our current practices to allegations of impropriety or illegality, or could require us to make changes in our facilities, equipment, personnel, services, capital expenditure programs and operating expenses. Current or future legislative initiatives or government regulation may have a material adverse effect on our operations or reduce the demand for our services.

In pursuing our growth strategy, we may expand our presence into new geographic markets. In entering a new geographic market, we will be required to comply with laws and regulations of jurisdictions that may differ from those applicable to our current operations. If we are unable to comply with these legal requirements in a cost-effective manner, we may be unable to enter new geographic markets.

We are subject to “anti-kickback” and “self-referral” laws and regulations that provide for criminal and civil penalties if they are violated.

The healthcare industry is subject to many laws and regulations designed to deter and prevent practices deemed by the government to be fraudulent or abusive. Unless an exception applies, Stark Law prohibits physicians from referring Medicare or Medicaid patients to providers of enumerated “designated health services” with whom the physician or a member of the physician’s immediate family has an ownership interest or compensation arrangement. Such referrals are deemed to be “self-referrals” due to the physician’s financial relationship with the entity providing the designated health services. Moreover, many states have adopted or are considering similar legislative proposals, some of which extend beyond the scope of the Stark Law to prohibit the payment or receipt of remuneration for the prohibited referral of patients for designated healthcare services and physician self-referrals, regardless of the source of the payment for the patient’s care.

We review our operations from time to time and believe that we are either exempted from or in compliance with the Stark Law and similar state statutes. We are currently working to implement a more systematic review process, which will ensure ongoing compliance. When evaluating strategic joint ventures or other collaborative relationships with physicians, we consider the scope and effect of these statutes and seek to structure the arrangements in full compliance with their provisions. Nevertheless, if it is determined that certain of our practices or operations violate the Stark Law or similar statutes, we could become subject to civil and criminal penalties, including exclusion from the Medicare and/or Medicaid programs. The imposition of any such penalties could harm our business.

We could fail to comply with the federal Emergency Medical Treatment and Active Labor Act, or EMTALA, which could subject us to civil monetary penalties or cause us to be excluded from participation in the Medicare program.

Our hospital facilities are subject to EMTALA, which requires every hospital participating in the Medicare program to conduct a medical screening examination of each person presented for treatment at its emergency room. If a patient is suffering from an emergency medical condition, the hospital must either stabilize that condition or make an appropriate transfer of the patient to a facility that can handle the condition, regardless of the individual’s ability to pay for care. EMTALA imposes severe penalties if a hospital fails to screen, appropriately stabilize or transfer a patient, or if a hospital delays service while first inquiring about the patient’s ability to pay. Such penalties include, but are not limited to, civil monetary penalties and exclusion from participation in the Medicare program. In addition to civil monetary penalties, an aggrieved patient, a patient’s family or a medical facility that ultimately suffers a financial loss as a direct result of a transferring hospital’s EMTALA violation can commence a civil suit under EMTALA. Although we believe that our facilities comply with EMTALA, there can be no assurances that claims will not be brought against us and, if successfully asserted against one or more of our hospitals, such claims could adversely affect our business and results of operations.

Our hospitals face competition for medical support staff, including nurses, pharmacists, medical technicians and other personnel, which may increase our labor costs and adversely affect our business.

We are highly dependent on our experienced medical support personnel, including nurses, pharmacists and lab technicians, seasoned local hospital management and other medical personnel. We compete with other healthcare providers to recruit and ultimately retain these healthcare professionals. On a national level, a shortage of nurses and other medical support personnel has become a significant operating issue for a number of healthcare providers. In the future, this shortage may require us to enhance wages and benefits to recruit and retain such personnel or require us to hire expensive temporary and per diem personnel. Additionally, to the extent that a significant portion of our employee base unionizes, or attempts to unionize, our labor costs could increase. If our wages and related expenses increase, we may not be able to raise our reimbursement rates correspondingly. Our failure to recruit and retain qualified hospital management, nurses and other medical support personnel or modulate our labor costs could adversely affect our results of operations and harm our business.

If we do not continually enhance our hospitals with the most recent technological advances in diagnostic and surgical equipment, our ability to maintain and expand our markets will be adversely affected.

There are ongoing technological advances regarding CT scanners, MRI equipment, positron emission tomography (“ PET ”) scanners and other similar equipment. In order to effectively compete, we must continually assess our equipment needs and upgrade when significant technological advances occur. If our hospitals do not stay abreast of the technological advances in the healthcare industry, patients may seek treatment from other providers and physicians may refer their patients to alternate sources.

If we are unable to effectively compete for patients, local residents could use other hospitals.

The hospital industry is highly competitive. In addition to the competition we face for acquisitions and physicians, we must also compete with other hospitals and healthcare providers for patients. The competition among hospitals and other healthcare providers for patients has intensified in recent years. Our hospitals are located in non-urban service areas. However, our hospitals face competition from hospitals outside of their primary service area, including hospitals in urban areas that provide more complex services. Patients in our primary service areas may travel to these other hospitals for a variety of reasons. These reasons include physician referrals or the need for services we do not offer. Patients who seek services from these other hospitals may subsequently shift their preferences to those hospitals for the services we provide.

Some of our hospitals operate in primary service areas where they compete with other hospitals. Some of these competing hospitals use equipment and services more specialized than those available at our hospitals. In addition, some competing hospitals are owned by tax-supported governmental agencies or not-for-profit entities supported by endowments and charitable contributions. These hospitals can make capital expenditures without paying sales, property and income taxes. We also face competition from other specialized care providers, including outpatient surgery, orthopedic, oncology and diagnostic centers.

We expect that these competitive trends will continue. Our inability to compete effectively with other hospitals and other healthcare providers could cause local residents to use other hospitals.

Risks Related to Our Common Stock

We have broad discretion in using our cash resources and may not use them in a manner that our stockholders would prefer.

We have broad discretion in how we use our limited cash resources. In general, our stockholders will not have the opportunity to evaluate the economic, financial or other information on which we base our decisions on how to use our cash resources. The choices of our Board of Directors and management on how to apply the funds could have a material adverse effect on our financial condition.

We may finance acquisitions by issuing additional capital stock or incurring substantial debt, both of which could have negative consequences.

As noted, we may use a portion of our resources to pursue acquisition opportunities and the timing, size and success of our acquisition efforts and any associated capital commitments cannot be readily predicted. We may raise additional funds to complete such acquisitions. Generally, our Board of Directors has the power to issue new equity (to the extent of authorized shares) without stockholder approval. If additional funds are raised through the issuance of equity securities, the percentage ownership of our then-current stockholders would be diluted, our earnings and book value per share could be diluted and, if such equity securities take the form of preferred stock, the holders of such preferred stock may have the rights, preferences or privileges senior to those of holders of Common Stock. If we are able to raise additional funds through the incurrence of debt, and we do so, we would likely become subject to restrictive financial covenants and other risks associated with the incurrence of debt.

The market for our Common Stock may be illiquid.

The 90-day average daily trading volume of our registered Common Stock in the over-the-counter markets derived from historical data reported by finance.google.com as of January 10, 2011 was approximately 141 shares and we have had some days with no trading. There can be no assurance that trading volumes will increase to a consistently higher level or that holders of the shares will be able to sell their shares in a timely manner or at all.

Our common stock is not listed on a national securities exchange.

Our Common Stock is currently traded on the Over The Counter Bulletin Board, commonly referred to as the “OTCBB,” and we do not currently meet the listing requirements for the NASDAQ Global Market or any other national securities exchange in the United States. The fact that our Common Stock is not listed for trading in such markets may have an effect on the perception of us among potential investors or acquirers and may adversely affect the liquidity of our shares and therefore can have an effect on our ability to complete such transactions or raise additional funds.

In the event we are unable to grow through acquiring or merging with other businesses or unable to obtain additional financing, our Common Stock may no longer meet listing requirements for the OTCBB and thereby eliminating any public market for our Common Stock.

Item 2.		PROPERTIES

The following principal facilities are leased by us and are material to our operations:

Facility		Address		Lease Term		Monthly Rent				Area (sq. ft.)
Outpatient Surgery Center		12264 El Camino Real, Suite 55 San Diego, California 92130		Lease expires 1/1/2016; one, seven year option to extend		$	20,169.07				6,684
RHA Home Office		3555 N.W. 58 th Street, Suite 700 Oklahoma City, Oklahoma 73112		Lease expires 11/30/2012		$	13,429.50				10,232
The Chandler Clinic		114 North Highway 18 Chandler, Oklahoma 74834		Lease expires 4/30/2014		$	7,417.50				4,470
Office Sublease from HSP, Inc.		433 N. Camden, Suite 810 Beverly Hills, California 90210		Lease expires 11/1/2012		$	4,800.00				1183.5
Physicians Clinic		2222 W. Iowa Avenue Chickasha, OK 73018		Lease expires 1/12/2030		$	60,325.00				65,800

Prior to January 2010, the Physicians Clinic was an owned facility. In January 2010, the facility was sold to Southern Plains Associates, LLC and leased backed to SPMC, an indirect wholly-owned subsidiary of RHA. The lease on The Chandler Clinic which was to expire in April 2014 was terminated on December 1, 2010 as the result of the sale of The Chandler Clinic operations. See Item 8, Footnote No. 17 “Subsequent Events”, for further discussion of the sale of “The Chandler Clinic” operations.

RHA operates three hospitals and one clinic in Oklahoma. The following properties are owned by RHA and are material to our operations as of September 30, 2010.

Facility		Address			Area (sq. ft.)
Hospital and Medical Office Buildings		1002 E. Central Boulevard Anadarko, Oklahoma 73005			57,887
Hospital and Medical Office Building		1101 S. Byrd Tishomingo, Oklahoma 73460			37,393
Hospital and Clinic		2308 Highway 66 West Stroud, Oklahoma 74079			33,333

The Hospital and Medical Office Building in Tishomingo, Oklahoma was sold effective January 6, 2011. See Item 8, Footnote No. 17, “Subsequent Events”, for further discussion of the sale of the Tishomingo building and the related operations.

Item 3.		LEGAL PROCEEDINGS

None.

Item 4.		SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

There was no Annual Meeting of Stockholders during the Fiscal Year Ending September 30, 2010.

PART II

Item 5.		MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER REPURCHASES OF EQUITY SECURITIES

MARKET INFORMATION

Our Common Stock is traded in the over-the-counter market under the symbol “FPCG.OB.” The following table presents, for the periods indicated, the high and low bid prices per share of our Common Stock. The quotations reflect inter-dealer prices, without retail mark-up, mark-down or commissions and may not represent actual transactions.

The Fiscal Year Ended September 30, 2010		High				Low
First Quarter		$	0.60			$	0.35
Second Quarter			0.65				0.20
Third Quarter			0.65				0.40
Fourth Quarter			0.65				0.23

The Fiscal Year Ended September 30, 2009		High				Low
First Quarter		$	0.75			$	0.15
Second Quarter			1.00				0.30
Third Quarter			0.70				0.50
Fourth Quarter			0.80				0.36

STOCKHOLDERS

As of January 31, 2011, and to the best of our records, there were approximately 200 stockholders of record of our Common Stock.

DIVIDENDS

We have never declared or paid cash dividends on our Common Stock or preferred stock. Holders of our Series 1-A Convertible Preferred Stock are entitled to non-cumulative dividends, if declared by the Board of Directors, of $0.20 per share annually. Holders of our Series 2-A Convertible Preferred Stock are entitled to non-cumulative dividends, if declared by the Board of Directors, in an amount equal to 8% of the price originally paid to us for each share of Series 2-A Convertible Preferred Stock. Holders of our Series 5-A Convertible Preferred Stock, par value $0.01 per share (the “ 5-A Preferred ”) are entitled to non-cumulative dividends, if declared by the Board of Directors, of $40 per share annually. Holders of our 6-A Preferred are entitled to non-cumulative dividends, if declared by the Board of Directors and pari passu with 5-A Preferred, of $40 per share annually. No dividend may be declared and paid upon shares of our Common Stock in any fiscal year unless dividends on all such preferred stock have been paid or declared and set aside for payment to holders of our preferred stock for such fiscal year. We currently intend to retain all future earnings to finance future growth and therefore do not anticipate declaring or paying any cash dividends in the foreseeable future.

EQUITY COMPENSATION PLAN INFORMATION

Number of securities

remaining available for

Number of securities

future issuance under

to be issued upon

Weighted-average

equity compensation

exercise of

exercise price of

plans (excluding

outstanding options,

outstanding options,

securities reflected in

warrants and rights at

warrants and rights

column (a)) at

Sep. 30, 2010

at Sep. 30, 2010

Sep. 30, 2010

Plan category

(a)

(b)

(c)

Equity compensation plans approved by security holders(2)(5)(6)(7)(8)(9)(10(11)

9,005,983

$

0.6129

9,682,601

Equity compensation plans not approved by security holders(1)(3)(4)

1,420,206

$

0.7773

12,579

Total

10,426,189

$

0.6353

9,695,180

(1)		In July 2000, our Board of Directors approved a stock option plan (the “ 2000 Plan ”). Our stockholders have not approved this plan. The 2000 Plan authorizes the grant of incentive stock options and non-statutory stock options covering an aggregate of 39,750 shares of Common Stock, as adjusted for our November 2002 reverse stock split (subject to limitations of applicable laws, and adjustment in the event of stock dividends, stock splits, reverse stock splits and certain other corporate events). The 2000 Plan expires on July 6, 2010, unless it is terminated earlier or suspended by the Board. The 2000 Plan is not subject to any provisions of the Employee Retirement Income Security Act of 1974. As of September 30, 2009, options to purchase an aggregate of 27,171 shares of Common Stock are classified as outstanding under the 2000 Plan, with a weighted average exercise price of $15.25. We do not intend to issue any further options under the 2000 Plan or warrants to purchase stock to additional individuals or vendors as compensation for services rendered.
(2)		In 2001, at our 2001 Annual Meeting, our stockholders approved two equity compensation plans: (a) our 2001 Stock Options/Stock Issuance Plan (the “ 2001 Plan ”) and (b) our Employee Stock Purchase Plan (“ ESPP ”). The maximum number of shares of Common Stock that may be issued under the 2001 Plan cannot exceed 20% of the total shares of Common Stock outstanding at the time the calculation is made (including, on an as-converted basis, all convertible preferred stock, convertible debt securities, warrants, options and other convertible securities that are exercisable), but in no event will the maximum number of shares of Common Stock which may be issued under the 2001 Plan as incentive stock options exceed 20,000,000. The weighted average exercise price under the 2001 Plan shall be fixed by the Plan Administrator (as that term is defined in the 2001 Plan) and, in the case of an incentive option, shall be limited by the following: 1) the exercise price per share shall not be less than 100% of the fair market value (as that term is defined in the 2001 Plan) per share of our Common Stock on the date of option grant and 2) in the event that the optionee is a 10% stockholder, then the exercise price per share shall not be less than 110% of the fair market value per share of Common Stock on the date of option grant. We have granted various incentive stock options as well as non-qualified stock options to key executives, management and other employees at exercise prices equal to or below the market price at the date of grant. As of September 30, 2009, based on the 20% calculation, the maximum number of shares issuable under the 2001 Plan was 17,756,180, and as of September 30, 2009, 9,682,601 shares remain available for issuance. The maximum number of shares of Common Stock that may be purchased under our ESPP is 350,000, with a weighted average exercise price of $1.48. As of September 30, 2009, we have discontinued offering the ESPP, no shares have been issued subsequent to the original issuance, and we currently have no intention to issue additional shares under the ESPP. Since its inception, a total of 22,940 shares of Common Stock have been purchased pursuant to the ESPP.
(3)		On November 20, 2001, our Board of Directors approved a grant of options to purchase a total of 3,750 shares (adjusted for reverse split) of our Common Stock at an exercise price of $2.00 per share to Robert N. Schwartz, one of the members of our Board of Directors.

(4)		On August 2, 2005, our Board of Directors approved the issuance of warrants to purchase an aggregate of 727,500 shares of our Common Stock at an exercise price of $0.35 per share to the seven initial members of our Advisory Board, as compensation for participation on our Advisory Board. The shares underlying these warrants became fully vested in August 2007. In August 2008, three of the initial Advisory Board members exercised their warrants in full and a total of 302,500 shares of Common Stock were issued. The other four initial Advisory Board members, holding an aggregate of 425,000 shares of Common Stock, allowed their warrants to expire unexercised. In December 2006, our Board of Directors approved the issuance of a warrant to purchase 50,000 shares of our Common Stock at an exercise price of $0.45 per share to Steven Spector, upon his addition as a member to the Advisory Board. The shares underlying the warrant issued to Mr. Spector became fully vested on December 12, 2008. The warrant issued to Mr. Spector expired unexercised on December 12, 2008. On September 11, 2007, our Board of Directors approved the issuance of warrants to purchase an aggregate of 350,000 shares of our Common Stock at an exercise price of $0.45 per share to six new members of our Advisory Board. The shares underlying these warrants became fully vested on September 13, 2009 and expired on September 13, 2009. On February 15, 2008, our Board of Directors approved the issuance of a warrant dated October 30, 2007, to purchase a total of 714,285 shares of our Common Stock at an exercise price of $0.45 per share to Brian Potiker, in consideration for his continued service as a member of our Advisory Board. The shares underlying the warrant issued to Mr. Potiker became fully vested on October 30, 2008, and the warrant was exercised on October 30, 2009. During the Fiscal Year Ended September 30, 2009, we issued warrants to purchase 125,000 shares of our Common Stock to individuals for participation on our Advisory Board. These warrants were issued at an exercise price of $0.625. One-third of the shares underlying the warrants vested immediately, one-third vest on March 16, 2010 and one-third vest on March 16, 2011. These warrants expire on March 16, 2012. As of September 30, 2009, all of these warrants remain outstanding. During the Fiscal Year Ended September 30, 2009, we issued warrants to purchase 150,000 shares of our Common Stock to a member of the newly-created Medical Advisory Board. These warrants were issued an exercise price of $0.625. One-third of the shares underlying the warrants vested immediately upon issuance on June 10, 2009, and the remaining two-thirds vest on June 10, 2010. These warrants expire on June 10, 2012. As of September 30, 2010, all of these warrants remain outstanding.
(5)		On November 17, 2005, our Board of Directors approved the grants of options to acquire an aggregate of 360,000 shares of our Common Stock at an exercise price of $0.40 per share to two independent directors. The shares underlying these options vested in quarterly increments over three years, beginning on the effective issuance date of August 1, 2005.
(6)		On July 1, 2008, our Compensation Committee approved the issuance of options to purchase 6,250,000 shares of our Common Stock to David Hirschhorn pursuant to the 2001 Plan. These options are exercisable for a period of seven years at an exercise price of $0.625 per share. Mr. Hirschhorn’s shares vest according to the following schedule: 1,250,000 shares vested on July 1, 2009; 1,250,000 shares vest on July 1, 2010; 1,250,000 shares vest on July 1, 2011; 1,250,000 shares vest on July 1, 2012 and the last 1,250,000 vest on July 1, 2013.
(7)		On November 10, 2008, in connection with Thomas Rice’s employment agreement, we entered into an Option Grant Agreement under which we granted Mr. Rice an incentive stock option to purchase up to 500,000 shares of Common Stock at an exercise price of $0.625 per share. Mr. Rice’s shares vest according to the following schedule: 125,000 shares vested immediately on November 10, 2008; 125,000 shares vested on November 10, 2009 and the remaining 250,000 shares vest on November 10, 2010. The option expires on November 15, 2015.
(8)		On April 22, 2009, pursuant to the terms of our 2001 Plan, we granted incentive stock options (the “ 2009 Employee Options ”) to 126 of our subsidiaries’ employees (the “ 2009 Employee Optionees ”) to purchase an aggregate of 1,319,390 shares of Common Stock in variable individual amounts. Pursuant to the terms of the Option Grant Agreements, and subject to the terms of the 2001 Plan, the shares of Common Stock subject to the 2009 Employee Options (the “ 2009 Employee Option Shares ”) vest according to the following schedule: (1) one-quarter vested immediately upon the date of issuance; (2) an additional one-quarter of the 2009 Employee Option Shares vest upon the passing of the one year anniversary of the date of issuance and (3) the remaining one-half of the 2009 Employee Option Shares vest upon the second anniversary of the date of issuance. The 2009 Employee Options were issued at an exercise price of $0.625 per share and are exercisable by the 2009 Employee Optionees with respect to all or any of the vested Shares until April 22, 2016, subject to the terms and conditions of the 2001 Plan and the related Option Grant Agreements. As of September 30, 2010, 420,308 of these options have been forfeited due to employee terminations.
(9)		On May 27, 2009, in connection with the employment of David Jamin as the administrator of RHA Stroud, LLC, we entered into an Option Grant Agreement, under which we granted to Mr. Jamin an incentive stock option to purchase up to 20,000 shares of Common Stock, at an exercise price of $0.625 per share, which option was to expire on May 27, 2016. Mr. Jamin’s option to purchase Common Stock vested incrementally on the following vesting schedule: (1) 6,667 shares vest on May 27, 2010; (2) 6,667 shares vest on May 27, 2011; and (3) 6,666 shares shall vest on May 27, 2012. As of September 30, 2010, 20,000 of these options have been forfeited due to the employee’s termination.

(10)		On December 29, 2009, in connection with Dan Chen’s employment agreement, we entered into an option grant agreement with Mr. Chen effective as of December 29, 2009, under which we granted to Mr. Chen an incentive stock option to purchase up to 500,000 shares of Common Stock, at an exercise price of $0.625 per share, which option shall expire on December 29, 2016. Mr. Chen’s option to purchase Common Stock vests incrementally on the following vesting schedule: (1) the option to purchase up to 100,000 shares vested immediately on December 29, 2009; (2) an option to purchase up to 100,000 shares vests incrementally on each anniversary date of the date of grant thereafter (with the final options vesting on the fourth anniversary date of the date of grant).
(11)		On June 14, 2010, in connection with Sean Kirrane’s employment agreement, we entered into an option grant agreement with Mr. Kirrane effective as of June 14, 2010, under which we granted to Mr. Kirrane an incentive stock option to purchase up to 150,000 shares of Common Stock, at an exercise price of $0.625 per share, which option sha11 expire on June 14, 2017. Mr. Kirrane’s option to purchase Common Stock vests incrementally on the following vesting schedule: (1) the option to purchase up to 30,000 shares vested immediately on June 14, 2010; (2) an option to purchase up to 30,000 shares vests incrementally on each anniversary date of the date of grant thereafter (with the final options vesting on the fourth anniversary date of the date of grant).

SALES OF UNREGISTERED EQUITY SECURITIES

On May 15, 2008, we sold and issued 25 shares of 5-A Preferred to an investor, pursuant to a Series 5-A Preferred Stock and Warrant Purchase Agreement. Such investor represented to us in writing that he was an “accredited investor,” as that term is defined in Rule 501 of Regulation D promulgated under the Securities Act. In connection with this issuance, we also issued warrants to purchase 15,000 shares of our Common Stock to an investor, pursuant to the same Series 5-A Preferred Stock and Warrant Purchase Agreement. These warrants are exercisable for a period of 2 years at an exercise price of $0.50 per share. Such investor represented to us in writing that he was an “accredited investor,” as that term is defined in Rule 501 of Regulation D promulgated under the Securities Act.

In May 2009, we accepted warrant exercises in the amount of 60,000 shares of Common Stock for an aggregate amount of $30,000 from one investor, who represented to us in writing that he is an “accredited investor,” as that term is defined in Rule 501(a) of Regulation D promulgated under the Securities Act. The shares were issued pursuant to the exercise of warrants originally issued on March 23, 2007, in connection with a private placement of our 5-A Preferred to various investors.

In September 2009, we accepted warrant exercises in the amount of 60,000 shares of Common Stock for an aggregate amount of $30,000 from two investors, each of whom represented to us in writing that he is an “accredited investor,” as that term is defined in Rule 501(a) of Regulation D promulgated under the Securities Act. The shares were issued pursuant to the exercise of warrants originally issued on August 10, 2007 and March 8, 2007 in connection with a private placement of our 5-A Preferred to various investors.

On May 21, 2010, we accepted warrant exercises in the amount of 60,000 shares (the “ Warrant Exercise Shares ”) of Common Stock, for an aggregate purchase price of $30,000 from one investor. The Warrant Exercise Shares were issued pursuant to the exercise of a warrant to purchase shares of Common Stock at an exercise price of $0.50 per share, in connection with the private placement of our Series 5-A Preferred Stock and warrants to purchase Common Stock. The investor represented to us in writing that he is an “Accredited Investor,” as that term is defined in Rule 501(a) of Regulation D, promulgated under the Securities Act of 1933, as amended (the “ Securities Act ”). The offers and sales of the Warrant Exercise Shares pursuant to the warrant exercises were exempt from the registration and prospectus delivery requirements of the Securities Act, by virtue of Section 4(2) of the Securities Act and Regulation D promulgated there-under.

Item 6.		SELECTED CONSOLIDATED FINANCIAL DATA

Not Applicable.

Item 7.		MANAGEMENT’S DISCUSSION & ANALYSIS OF RESULTS OF OPERATIONS

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and the related notes thereto appearing elsewhere in this Form 10-K.

FORWARD LOOKING STATEMENTS

The information set forth in this “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” contains certain forward-looking statements. Please refer to “SPECIAL NOTE REGARDING FORWARD- LOOKING STATEMENTS” at the beginning of this Form 10-K for more information about forward-looking statements.

We undertake no obligation to release publicly the results of any future revisions we may make to forward-looking statements to reflect events or circumstances after the date of this report or to reflect the occurrence of unanticipated events.

OVERVIEW

From 2001 to November 2004, we provided Fortune 500 and Global 500 companies with BPO solutions into and across the Asia-Pacific region. In November 2004, our active business operations ceased with the sale of our BPO operations in Asia.

On December 2, 2005, we resumed active operations through newly created indirect subsidiaries, and we entered into two separate purchase agreements to acquire from Surgical Ventures, Inc., a California corporation, a controlling interest in Del Mar and Point Loma, two separate outpatient surgical centers in the San Diego ambulatory surgical centers. In June 2007, we consolidated the operations of the San Diego ambulatory surgical centers at the Del Mar facility.

On October 29, 2007, we acquired 51% of the issued and outstanding membership units of RHA. Based in Oklahoma City, RHA owns and operates three critical access hospitals, one medical clinic and an ancillary support services units all focused the delivery of healthcare services to rural communities in Oklahoma. On May 1, 2008, RHA completed a material acquisition with the purchase of SPMC, a multi-specialty physician practice, also located in Oklahoma. Beginning November 18, 2008, RHA began operating under the trade name “Southern Plains Medical Group.” On December 11, 2008, through a wholly-owned subsidiary, we acquired the remaining 49% of the issued and outstanding membership units of RHA, thus making RHA an indirect wholly-owned subsidiary of ours.

CHANGE IN THE FISCAL YEAR END

In November 2007, our Board of Directors approved a change to our fiscal year end from January 31 to September 30. In view of this change, this report includes the twelve-month periods ended September 30, 2010 and 2009, data for all periods are derived from our audited consolidated financial statements.

FUNDING

We have sustained operating losses since our inception and had an accumulated deficit of approximately $95.5 million as of September 30, 2010, which has been funded primarily through the issuance of preferred stock, the issuance of promissory notes and cash generated from operations.

As of September 30, 2010 we had current liabilities of $10.3 million and current assets of $6.5 million.

In December 2008, subsidiaries of RHA completed the 2008 Loans. The completion of the 2008 Loans, which carry amortization schedules of 16 years to 20 years and are guaranteed up to 80% by the USDA, had the effect of reducing our current liabilities by $4.6 million.

In 2009, we completed a bridge financing transaction (the “ Bridge Financing ”) for $2.2 million, which was consummated in three separate closings. The notes were due and payable as follows: $1.5 million was due on November 6, 2009, $0.5 million was due on December 3, 2009, $0.1 million was due on December 31, 2009 and $50,000 was due on January 14, 2010. On the due dates of the $1.5 million due on November 6, 2009, the $0.5 million due on December 3, 2009 and the $0.1 million due on December 31, 2009, we exercised our right to extend the due dates to February 6, 2010, March 3, 2010 and March 31, 2010, respectively. On the extended due dates, we exercised our right to again extend the due dates. The $1.5 million previously due on February 6, 2010, was extended to provide for $0.5 million to be due August 6, 2011 and $1 million to be due February 6, 2013. The $0.5 million previously due on March 3, 2010 was extended to provide for $0.2 million to be due on September 3, 2011 and $0.3 million to be due on March 3, 2013. The $150,000 previously due March 31, 2010 was extended to provide for $100,000 to be due March 31, 2013 and $50,000 to be due September 30, 2011. The $50,000 previously due April 4, 2010 was extended to be due April 14, 2013.

As disclosed in an August 10, 2010 press release, the Company, as part of its strategic growth plan entered into various Letters of Intent to acquire new operations with new capital and divest other existing operations that no longer fit its strategic profile moving forward or no longer provided any attractive return on capital or was creating a significant drag on operational performance and company liquidity.

The poorly performing units at the Company have put liquidity pressure on the better performing facilities. The Company was not able to grow into its cost structure in Oklahoma. Consequently, we are eliminating poorly performing facilities and the related infrastructure necessary to support them specifically as it relates to our Oklahoma facilities.

An inability to complete our re-organization would have necessitated a mandatory capital infusion to sustain our operations in Fiscal 2011. Management intends to continue to prune its balance sheet in fiscal 2011 and expand its capital base as appropriate or necessary for operations and/or its transaction needs.

Our recurring losses from operations and anticipated future losses raise substantial doubt about our ability to continue as a going concern. Our plan of operations, even if successful, may not result in cash flow sufficient to finance our business. Realization of our assets is dependent upon our continued operations, which in turn is dependent upon meeting financing requirements and the success of future operations.

Our ability to continue as a going concern is dependent on improving profitability and cash flow and securing additional financing. While we believe in the viability of our strategy to raise additional funds and that the actions presently being taken provide the opportunity to continue as a going concern, there can be no assurances to that effect.

CRITICAL ACCOUNTING POLICIES

We prepare our consolidated financial statements in conformity with accounting principles generally accepted in the United States of America. As such, we are required to make certain estimates, judgments and assumptions that we believe are reasonable based upon the information available. These estimates and assumptions affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the periods presented. The significant accounting policies which we believe are the most critical to aid in fully understanding and evaluating our reported financial results include the following:

Accounts Receivable

Accounts receivable are reported at estimated net realizable amounts from services rendered from federal and state agencies (under the Medicare and Medicaid programs), managed care health plans, commercial insurance companies, workers’ compensation, employers and patients. A significant portion of our revenues are concentrated with federal and state agencies.

Additions to the allowance for doubtful accounts are made by means of the line item “Provision for Doubtful Accounts” in our financial statements. We write off uncollectible accounts against the allowance for doubtful accounts after exhausting collection efforts and adding subsequent recoveries. Net accounts receivable include only those amounts we estimate we will collect.

We perform an analysis of our historical cash collection patterns and consider the impact of any known material events in determining the allowance for doubtful accounts. In performing our analysis, we considered the impact of any adverse changes in general economic conditions, business office operations, payor mix, or trends in federal or state governmental healthcare coverage.

Impairment of Goodwill and Long-lived Assets

We review long-lived assets, certain identifiable intangible assets and goodwill related to these assets for impairment. For assets to be held and used, including acquired intangibles, we initiate a review whenever events or changes in circumstances indicate that the carrying value of a long-lived asset may not be recoverable and annually for goodwill and other intangible assets not subject to amortization. Recoverability of an asset is measured by comparison of its carrying value to the future undiscounted cash flows that the asset is expected to generate. Any impairment to be recognized is measured by the amount by which the carrying value exceeds the projected discounted future operating cash flows. Assets to be disposed of and for which management has committed a plan to dispose of the assets, whether through sale or abandonment, are reported at the lower of carrying value or fair value less costs to sell.

In the Fiscal Year Ended September 30, 2010, we determined there was no impairment of Goodwill, however we recorded an impairment of $187,000 of the intangible assets of The Chandler Clinic arising from the sale of the operation on December 1, 2010. See Item 8, Footnote No. 17, “Subsequent Events” for a discussion of the sale of The Chandler Clinic.

In the Fiscal Year Ended September 30, 2009, we determined that an impairment of the goodwill previously recorded upon the acquisition of RHA had occurred. An impairment charge of $209,000 was recorded. In the Fiscal Year Ended September 30, 2008, we recorded an impairment of $308,000 with respect to fixed assets at Point Loma arising from the termination of activities at this facility as part of our review of long-lived assets, certain identifiable intangible assets and goodwill.

Revenue Recognition

We recognize revenue when persuasive evidence of an arrangement exists, delivery or performance has occurred, the sales price is fixed or determinable and collectability is probable or reasonably assured.

Income Taxes

The asset and liability approach is used to account for income taxes by recognizing deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of assets and liabilities. We record a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be realized.

Accounting for Uncertainty in Income Taxes

Financial Accounting Standards Board (“ FASB ”) Accounting Standards Codification (“ ASC ”) 740 creates a single model to address accounting for uncertainty in tax positions by prescribing a minimum recognition threshold a tax position is required to meet before being recognized in the financial statements. FASB ASC 740 also provides guidance on de-recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition. There are no unrecognized tax benefits to disclose in the notes to the consolidated financial statements.

Stock-Based Compensation

Effective February 1, 2006, we adopted the fair value recognition provisions of FASB ASC 718, “Accounting for Compensation Arrangements,” using the modified prospective application method. Our stock option plans are described in Note 15 to our financial statements contained in Item 8 of this Form 10-K.

Earnings Per Share

Basic earnings/(loss) per share is computed by dividing net income/(loss) by the weighted average shares of Common Stock outstanding during the year. Diluted earnings per share is computed by dividing net income by the weighted average shares of Common Stock and potential common shares outstanding during the year. Potential common shares outstanding consist of dilutive shares issuable upon the conversion of our preferred stock to Common Stock as computed using the if-converted method and the exercise of outstanding options and warrants to purchase Common Stock, computed using the treasury stock method.

Recent Accounting Pronouncements

In December 2007, the FASB issued guidance on “Non-controlling Interests in Consolidated Financial Statements—an amendment of ARB No. 51.” This guidance requires companies with non-controlling interests to disclose such interests clearly as a portion of equity but separate from the parent’s equity. The non-controlling interest’s portion of net income must also be clearly presented on the income statement. This is effective for financial statements issued for fiscal years beginning after December 15, 2008 and was adopted by us in the first quarter of fiscal year 2010. The adoption of the new rules did not have a material impact on our financial condition or results of operation.

In December 2007, the FASB issued updated guidance on business combinations. This guidance applies the acquisition method of accounting for business combinations where the acquirer gains a controlling interest, regardless of whether consideration was exchanged. The updated guidance requires the acquirer to fair value the assets and liabilities of the acquiree and record goodwill on bargain purchases and is effective for financial statements issued for fiscal years beginning after December 15, 2008 and was adopted by us in the first quarter of fiscal year 2010. The adoption did not have a material impact on our financial condition or results of operation.

In January 2010, new guidance was issued regarding improving disclosures about fair value measurements. This standard amends the disclosure guidance with respect to fair value measurements for both interim and annual reporting periods. Specifically, this standard requires new disclosures for significant transfers of assets or liabilities between Level 1 and Level 2 in the fair value hierarchy; separate disclosures for purchases, sales, issuance and settlements of Level 3 fair value items on a gross rather than net, basis; and more robust disclosure of the valuation techniques and inputs used to measure Level 2 and Level 3 assets and liabilities. Except for the detailed disclosures of changes in Level 3 items, which will be effective as of October 1, 2011, the remaining new disclosure requirements are effective as of October 1, 2010.

Fair Value of Financial Instruments

Carrying amounts of certain of our financial instruments, including cash equivalents, accounts receivable and accounts payable approximate fair value due to their short maturities. Carrying value of notes payable and long-term debt approximate fair values as they bear market rates of interest. None of our financial instruments are held for trading purposes.

RESULTS OF OPERATIONS (All amounts in thousands)

		Fiscal				Fiscal
		Year				Year
		Ended				Ended
		September 30,				September 30,
		2010				2009
Revenue from services		$	39,502			$	39,090
Selling, general and administrative expenses and provision for doubtful accounts			44,152				44,075
Amortization of stock-based compensation			1,078				1,245
Impairment of long-lived assets and goodwill			187				209
Depreciation and amortization			1,383				1,102
Total costs and expenses			46,800				46,631
Operating loss			(7,298	)			(7,541	)
Other income (expense)			453	)			(281	)
Interest income			42				42
Interest expense			(2,012	)			(2,094	)
Net loss from operations before taxation and non-cash beneficial conversion feature			(8,815	)			(9,874	)
Non-controlling interest			(681	)			(177	)
Net loss before non-cash beneficial conversion feature			(9,496	)			(10,051	)
Non-cash beneficial conversion feature preferred dividend			(48	)			(317	)
Net loss allocable to common stockholders		$	(9,544	)		$	(10,368	)

MANAGEMENT’S DISCUSSION & ANALYSIS OF RESULTS OF OPERATIONS — FISCAL YEAR ENDED SEPTEMBER 30, 2010 COMPARED TO YEAR ENDED SEPTEMBER 30, 2009

Revenue

Revenue of $39.5 million was generated in the Fiscal Year Ended September 30, 2010 compared with $39.1 million in the Fiscal Year Ended September 30, 2009, an increase of 1.02%, primarily due to the inclusion of a full year of The Chandler Clinic operations during Fiscal Year Ended September 30, 2010 and only five months during Fiscal Year Ended September 30, 2009.

Selling, General and Administrative Expenses and Provision for Doubtful Accounts

Selling, general and administrative expenses, including provision for doubtful accounts, consisted primarily of employee-related costs that are directly related to providing goods or services, such as salaries and benefits of administrative and support personnel, rental, insurance premiums and costs relating to other outside services.

Selling, general and administrative expenses and provision for doubtful accounts totaled $44.2 million in the Fiscal Year Ended September 30, 2010 and $44.1 million in the Fiscal Year Ended September 30, 2009. Operating efficiencies realized at the parent company and RHA were offset by additional operating expenses at Del Mar which was commensurate with the increase in revenue.

Amortization of Stock-Based Compensation

Amortization of stock-based compensation consists of the expense incurred as the grant of options and warrants to purchase common stock vest over the term of the grant agreements. Since 2006, we have granted to officers, employees and members of our Advisory Board options to purchase our common stock.

We granted options to purchase 650,000 and 1,839,390 shares of our common stock during the Fiscal Years ended September 30, 2010 and 2009 respectively. As a result of the decreased number of shares granted during the Fiscal Year ended September 30, 2010 and the related vesting schedules, the amortization of stock-based compensation expense decreased to $1,078,000 during the Fiscal Year ended September 30, 2010 from $1,245,000 during the Fiscal Year ended September 30, 2009.

See Item 8, Footnote No. 14, “Stock Options” for a discussion of our stock option plans and stock-based compensation.

Impairment of Long-Lived Assets and Goodwill

In the Fiscal Year Ended September 30, 2010, we determined there was no impairment of Goodwill, however we recorded an impairment of $187,000 of the intangible assets of The Chandler Clinic arising from the sale of the operations on December 1, 2010. See Item 8, Footnote No. 17, “Subsequent Events”, for a discussion of the sale of The Chandler Clinic. In the Fiscal Year Ended September 30, 2009, we determined that an impairment of the goodwill previously recorded upon the acquisition of RHA had occurred. An impairment charge of $209,000 was recorded.

Operating Loss

As a result of the foregoing, we had an operating loss in the Fiscal Year Ended September 30, 2010 of $7.3 million compared to an operating loss of $7.5 million in the Fiscal Year Ended September 30, 2009, or a decrease of 3.2%. The operating loss decreased as a result of operating efficiencies achieved at the parent company and RHA and revenue growth at Del Mar.

Other Income (Expense)

In Fiscal Year Ended September 30, 2010, we received $429,000 of insurance proceeds which were a reimbursement for tornado damage at one of our critical access hospitals.

We had no gain or loss from the sale of assets in the Fiscal Year Ended September 30, 2010. We recognized a $281,000 loss from the sale of a 10.9% equity interest in Del Mar in the Fiscal Year Ended September 30, 2009.

Interest Income

We had interest income of $42,000 in the Fiscal Year Ended September 30, 2010 and $42,000 in the Fiscal Year Ended September 30, 2009.

Interest Expense

We recorded interest expense of $2.0 million in the Fiscal Year Ended September 30, 2010 and $2.1 million in the Fiscal Year Ended September 30, 2009, reflecting a decrease of 4.8%. This decrease was due primarily to a decrease in the interest rate on the Bridge Financing.

Non-Controlling Interest

In the Fiscal Year Ended September 30, 2010, non-controlling interest amounted to ($0.7) million, compared to ($0.2) million for the Fiscal Year Ended September 30, 2009. The increase in non-controlling interest over the prior years is due to improved earnings at Del Mar coupled with the increased ownership share of Del Mar non-controlling interests.

Taxation

FASB ASC 740 creates a single model to address accounting for uncertainty in tax positions by prescribing a minimum recognition threshold that a tax position is required to meet before being recognized in the financial statements. FASB ASC 740 also provides guidance on de-recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition. There are no unrecognized tax benefits to disclose in the notes to the consolidated financial statements.

Net Income or Loss Before Non-Cash Beneficial Conversion Feature

As a result of the foregoing, we recorded a net loss of $9.5 million and $10.1, in the Fiscal Years Ended September 30, 2010 and 2009 respectively, a decrease of $0.6 million or 5.9% The net loss decreased as a result of operating efficiencies achieved at the parent company and RHA and revenue growth at Del Mar.

Non-Cash Beneficial Conversion Feature Preferred Dividend

In the Fiscal Year Ended September 30, 2010, we recognized a $48,000 non-cash beneficial conversion feature preferred dividend expense compared to $317,000 in the Fiscal year Ended September 30, 2009, relating to the issuance of our 5-A Preferred and 6-A Preferred, each together with warrants, during the periods. The expense, which arose from a beneficial conversion feature resulting from the fact that such convertible securities could be converted into our Common Stock at an amount below its market price on the commitment date of the securities, was recognized in accordance with FASB standards on accounting for convertible securities with beneficial conversion features.

Net Income or Loss Allocable to Common Stockholders

Net income or loss allocable to common stockholders is computed from net income or loss and adding or deducting deemed non-cash dividend to preferred stockholders and credit on exchanges. We had net loss allocable to common stockholders of $9.5 million, or ($0.64) per basic share in the Fiscal Year Ended September 30, 2010, compared with $10.4 million, or $(0.94) per basic share in the Fiscal Year Ended September 30, 2009.

LIQUIDITY AND CAPITAL RESOURCES

Our cash and cash equivalents totaled $1.7 million as of September 30, 2010, compared with $2.3 million as of September 30, 2009.

At September 30, 2010, we had a working capital deficit of $3.7 million and a stockholders’ deficit of $16.4 million, as compared to a working capital of $1.8 million and a stockholders’ deficit of $9.0 million at September 30, 2009. We have long-term liabilities of $16.6 million as of September 30, 2010, compared to $12.4 million as of September 30, 2009. To date, we have financed our operations primarily through sales of preferred and common equity, issuance of promissory notes, and cash from operations.

Net cash used in operating activities totaled $2.9 million in the Fiscal Year Ended September 30, 2010, compared with $3.5 million in the Fiscal Year Ended September 30, 2009. The decrease in net cash used in the Fiscal Year Ended September 30, 2010 arose from the decrease in the net operating loss during the Fiscal Year Ended September 30, 2010.

Net cash provided in (used) by investing activities in the Fiscal Year Ended September 30, 2010 was $1.4 million, compared to ($4.3) million in the Fiscal Year Ended September 30, 2009. During the Fiscal Year Ended September 30, 2010, cash was provided by the removal of restrictions on $1.5 million of cash held on deposit with the former debt holder on the SPMC building. The net cash used by investing in the Fiscal Year Ended September 30, 2009 was primarily due to the purchase of real property for our hospital located in Stroud, Oklahoma and the acquisition of the remaining membership units in RHA, which we did not previously own.

Net cash provided by financing activities was $0.9 million in the Fiscal Year Ended September 30, 2010, compared with $7.2 million in the Fiscal Year Ended September 30, 2009. Net cash provided by financing activities in the Fiscal Years Ended September 30, 2010 and 2009 was provided primarily by the issuance of promissory notes. At September 30, 2010, we had total liabilities of $28.6 million and assets of $25.7 million.

Our recurring losses from operations and anticipated future losses raise substantial doubt about our ability to continue as a going concern. Our plan of operations, even if successful, may not result in cash flow sufficient to finance our business. Realization of our assets is dependent upon our continued operations, which in turn is dependent upon meeting financing requirements and the success of future operations.

Our ability to continue as a going concern is dependent on improving profitability and cash flow and securing additional financing. While we believe in the viability of our strategy to raise additional funds and that the actions presently being taken provide the opportunity to continue as a going concern, there can be no assurances to that effect.

OFF-BALANCE SHEET FINANCING

We currently have no “off-balance sheet” financing arrangements, other than operating leases.

DISCLOSURE OF CONTRACTUAL OBLIGATIONS

Contractual Obligations (in thousands)

		Payments due by period
		Total				Less than 1 year				1-3 years				3-5 years				More than 5 years
Long-term debt obligations		$	18,539			$	2,083			$	5,221			$	1,139			$	10,096
Capital lease obligations			389				192				181				16				—
Operating lease obligations			4,225				1,328				2,062				760				75
Other contractual obligations			8				8				—				—				—
Total		$	23,161			$	3,611			$	7,464			$	1,915			$	10,171

“Other contractual obligations” consist primarily of obligations to purchase goods or services that are enforceable and legally binding on us. These obligations specify all significant terms and are not cancelable without a penalty. Our obligations primarily relate to software licensing, clinical coding, medical waste removal, equipment maintenance and linen service.

Item 7A.		QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

INTEREST RATE RISK

Our exposure to market risk for changes in interest rates relates primarily to our cash on deposit with high quality financial institutions and a portion of our long-term debt that is based on prime rates. We are exposed with respect to interest rate fluctuations in the U.S. as changes in U.S. interest rates affect the interest earned on our cash and interest paid on our debt.

FOREIGN CURRENCY RISK

We derive our revenues from operations in the United States. All of our revenues are currently denominated in U.S. dollars. An increase or decrease in the value of the U.S. dollar relative to foreign currencies does not have a material impact on the demand for our services or on our expenses. Currently, we do not hedge against any foreign currencies and, as a result, could incur unanticipated gains or losses.

Item 8.		CONSOLIDATED FINANCIAL STATEMENTS

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Stockholders
First Physicians Capital Group, Inc.

We have audited the accompanying consolidated balance sheets of First Physicians Capital Group, Inc. (the “Company”), as of September 30, 2010 and 2009, and the related consolidated statements of operations, changes in stockholders’ equity (deficit), and cash flows for the years then ended. The Company’s management is responsible for these financial statements. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of their internal control over financial reporting. An audit includes consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. Our audits of the financial statements included examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company, as of September 30, 2010 and 2009, and the results of their operations and their cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As shown in the financial statements, the Company incurred a net loss of $9,544,000 during the year ended September 30, 2010, and, as of that date, had a working capital deficiency of $3,716,000. As noted in footnote 1 to the financial statements, the recurring losses from operations and anticipated future losses raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

/s/ Whitley Penn LLP
Dallas, Texas
February 14, 2011

FIRST PHYSICIANS CAPITAL GROUP, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except per share data)

		September 30,				September 30,
		2010				2009
ASSETS
Current assets:
Cash and cash equivalents		$	1,667			$	2,324
Restricted cash			—				1,523
Accounts receivable, net of allowance for uncollectible accounts			3,787				4,891
Prepaid expenses			123				111
Other current assets			968				1,772
Total current assets			6,545				10,621
Property and equipment, net			17,557				17,033
Goodwill (Note 8)			759				759
Other assets			869				1,078
Total assets		$	25,730			$	29,491
LIABILITIES, PREFERRED STOCK AND STOCKHOLDERS’ EQUITY/ (DEFICIT)
Current liabilities:
Accounts payable		$	4,338			$	3,598
Accrued expenses			3,663				3,515
Notes payable			—				4,309
Current maturities of long term debt			2,260				1,028
Total current liabilities			10,261				12,450
Long term debt, net of current portion			16,637				12,441
Deferred Gain			1,705				—
Total liabilities			28,603				24,891
Commitments and contingencies
Non-redeemable preferred stock:
Preferred stock Series 1-A ($0.01 par value, 2,802,000 shares authorized; 67,600 shares issued and outstanding as of September 30, 2010 and 2009)			166				166
Preferred stock Series 2-A ($0.01 par value, 1,672,328 shares authorized; 3,900 shares issued and outstanding as September 30, 2010 and 2009)			25				25
Total non-redeemable preferred stock			191				191
Redeemable preferred stock: (Note 14)
Preferred stock Series 5-A ($0.01 par value, 5,000,000 shares authorized; 9,000 and 8,987 shares issued and outstanding as of September 30, 2010 and 2009, respectively)			7,832				7,819
Preferred stock Series 6-A ($0.01 par value, 5,000 shares authorized; 4,875 and 4,957 shares issued and outstanding as of September 30, 2010 and September 30, 2009, respectively)			4,381				4,463
Total redeemable preferred stock			12,213				12,282
Stockholders’ deficit and Non-controlling interests:
Common stock ($0.01 par value, 100,000,000 shares authorized; 15,049,507 and 13,448,683 shares issued and outstanding as of September 30, 2010 and September 30, 2009, respectively)			153				136
Additional paid-in-capital			79,235				77,109
Accumulated deficit			(95,666	)			(86,122	)
Treasury stock, at cost (149,744 and 93,494 shares as of September 30, 2010 and September 30, 2009 respectively)			(104	)			(79	)
Total First Physicians Capital Group Stockholders’ Deficit:			(16,382	)			(8,956	)
Non-controlling interests (Note 11)			1,105				1,083
Total Stockholder’s Deficit			(15,277	)			(7,873	)
Total liabilities, preferred stock and stockholders’ deficit and Non-controlling interests		$	25,730			$	29,491

The accompanying notes are an integral part of these Consolidated Financial Statements.

FIRST PHYSICIANS CAPITAL GROUP, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)

		Fiscal				Fiscal
		Year				Year
		Ended				Ended
		September 30,				September 30,
		2010				2009
Revenue from services		$	39,502			$	39,090
Cost and expenses:
Selling, general and administrative expenses			44,153				44,075
Amortization of stock-based compensation (Note 15)			1,077				1,245
Impairment of long-lived assets and goodwill			187				209
Depreciation and amortization			1,383				1,102
Total costs and expenses			46,800				46,631
Operating loss			(7,298	)			(7,541	)
Interest income			42				42
Interest expense			(2,012	)			(2,094	)
Other income (expense)			453				(281	)
Non-controlling interests			(681	)			(177	)
Net loss from operations before taxation and non-cash beneficial conversion feature			(9,496	)			(10,051	)
Taxation			—				—
Non-cash beneficial conversion feature preferred dividend			(48	)			(317	)
Net loss allocable to common stockholders		$	(9,544	)		$	(10,368	)
Net loss per common share:
Basic		$	(0.64	)		$	(0.94	)
Diluted			N/A				N/A

The accompanying notes are an integral part of these Consolidated Financial Statements.

FIRST PHYSICIANS CAPITAL GROUP, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY/(DEFICIT)
(in thousands, except for shares data)

										Additional								Other								Total
		Common Shares								Paid-in				Accumulated				Comprehensive				Treasury				Stockholders’
		Stock				Amount				Capital				Deficit				Income (Loss)				Stock				Deficit
Balance at Sept. 30, 2008			10,322,927			$	103			$	71,301			$	(75,702	)		$	(52	)		$	0			$	(4,350	)
Net Loss															(10,368	)											(10,368	)
Issuance of Common Stock			160,000				2				98																100
Conversion of Series B Preferred to Common Stock			2,384,250				25				2,477																2,502
Proceeds from exercise of warrants			525,000				5				258																263
Beneficial Conversion Feature related to preferred stock issuance											317																317
Stock based compensation			150,000				1				1,244																1,245
Issuance of warrants as discount on convertible debt											1,184																1,184
Equity transactions in consolidated affiliates (see note 11)											230																230
Purchase of treasury stock			(93,494	)																			(79	)			(79	)
Balance at Sept. 30, 2009			13,448,683			$	136			$	77,109			$	(86,070	)		$	(52	)		$	(79	)		$	(8,956	)
Net Loss															(9,596	)			52								(9,544	)
Issuance of Common Stock			200,000				2				98																100
Conversion of 6-A Preferred to Common Stock			400,000				4				121																125
Proceeds from exercise of warrants			1,105,685				11				492																503
Cancellation of Restricted Shares			(48,611	)																							—
Purchase of treasury stock			(56,250	)																			(25	)			(25	)
Issuance of warrants with 5-A Preferred Stock											11																11
Issue of warrants with 6-A Preferred Stock											36																36
Bridge Loan Warrant Extension											291																291
Stock based Compensation											1,077																1,077
Balance at Sept. 30, 2010			15,049,507			$	153			$	79,235			$	(95,666	)		$	—			$	(104	)		$	(16,382	)

The accompanying notes are an integral part of these Consolidated Financial Statements.

FIRST PHYSICIANS CAPITAL GROUP, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)

		Fiscal				Fiscal
		Year				Year
		Ended				Ended
		September 30,				September 30,
		2010				2009
Cash flows from operating activities:
Net loss		$	(9,496	)		$	(10,051	)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-controlling interest			681				177
Depreciation and amortization			1,383				1,102
Bad debt provision			5,914				4,561
Amortization of stock-based compensation			1,077				1,245
Amortization of debt discount			522				952
Amortization of deferred gain on sale of assets			(55	)			—
Loss from sale of investments			—				281
Impairment of long-lived assets and goodwill			187				209
Changes in working capital components:
Accounts receivable			(4,810	)			(3,163	)
Accounts payable and accrued expenses			888				1,455
Other			812				(275	)
Net cash used in operating activities			(2,897	)			(3,507	)
Cash flows from investing activities:
Purchase of property and equipment			(1,906	)			(4,515	)
Purchase of equity interest in consolidated affiliate			—				(35	)
Deferred gain from sale of property and equipment			1,760				—
Proceeds from sale of equity interests in consolidated affiliate			—				325
Decrease (increase) in restricted cash			1,523				(9	)
Acquisition of subsidiaries, net of cash acquired			—				(55	)
Net cash provided by (used in) investing activities			1,377				(4,289	)
Cash flows from financing activities:
Borrowings on convertible loans			—				2,200
Payments on long term debt			(4,961	)			(5,786	)
Proceeds from notes payable			5,849				10,246
Distributions to non-controlling interests			(659	)			(144	)
Purchase of treasury stock			(25	)			(79	)
Proceeds from exercise of stock warrants			503				263
Proceeds from issuance of preferred stock, net of cost			56				350
Proceeds from issuance of common stock			100				100
Net cash provided by financing activities			863				7,150
Net decrease in cash and cash equivalents			(657	)			(646	)
Cash and cash equivalents at beginning of year			2,324				2,970
Cash and cash equivalents at end of year		$	1,667			$	2,324
Supplemental cash flow information:
Cash paid for interest		$	1,356			$	1,204
Cash paid for taxes			—				—

During the Fiscal Year ended September 30, 2009, there was a non-cash transaction which involved the purchase of the 49% minority interest in RHA (as that term is defined herein) for a promissory note of $1,800,000, with the first payment of $50,000 paid at closing.

During the Fiscal Year ended September 30, 2009, the fair value of warrants issued in conjunction with the convertible notes amounted to $932,000. The beneficial conversion feature associated with the convertible notes amounted to $253,000.

During the Fiscal Year ended September 30, 2009, the fair value of warrants issued in conjunction with the issuance of preferred stock amounted $84,473. The beneficial conversion feature associated with the preferred stock amounted to $317,000.

During the Fiscal Year ended September 30, 2010, the fair value of warrants issued in conjunction with the extension of the convertible notes which were issued in connection with the bridge financing we entered into during the fiscal year ended September 30, 2009 amounted to $291,000.

The accompanying notes are an integral part of these Consolidated Financial Statements.

FIRST PHYSICIANS CAPITAL GROUP, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1. Company Background

We were originally incorporated in Nevada in October 1980 and re-incorporated in Delaware in November 2000. From 2001 to November 2004, we provided Fortune 500 and Global 500 companies with customizable and comprehensive business process outsourcing (“ BPO ”) solutions into and across the Asia-Pacific region. In November 2004, our active business operations ceased with the sale of our BPO operations in Asia.

On December 16, 2005, at our Annual Meeting of Stockholders, our stockholders voted to amend our Certificate of Incorporation to change our legal name from “Vsource, Inc.” to “Tri-Isthmus Group, Inc.” (“ TIGroup ”) and to reduce the number of authorized shares of our common stock, par value $0.01 per share (the “ Common Stock ”), from 500,000,000 shares to 100,000,000 shares, as described in our Proxy Statement filed with the Securities and Exchange Commission (the “ SEC ”) on November 28, 2005. The reduction of the number of authorized shares of our Common Stock did not affect the number of shares of Common Stock issued and outstanding.

During the fiscal year ended January 31, 2007 (the “ Fiscal Year Ended January 31, 2007 ”), we resumed active operations following the acquisition of two ambulatory surgical centers located in Southern California. On December 2, 2005, through newly created indirect subsidiaries, we entered into two separate purchase agreements to acquire from Surgical Ventures, Inc., a California corporation, a controlling interest in two separate outpatient surgical centers in San Diego, California, Point Loma Surgical Center, L.P. and Outpatient Surgery of Del Mar, L.P., and we completed these acquisitions on November 16, 2006. On February 9, 2007, we converted these limited partnerships into Outpatient Surgery of Point Loma, L.L.C. (“ Point Loma ”) and Outpatient Surgery of Del Mar, L.L.C. (“ Del Mar ,” and, together with Point Loma, the “ San Diego ambulatory surgical centers ”), respectively. In June 2007, we consolidated the operations of the San Diego ambulatory surgical centers at the Del Mar facility.

On October 29, 2007, we acquired 51% of the issued and outstanding membership units of Rural Hospital Acquisition, LLC, an Oklahoma limited liability company (“ RHA ”). Based in Oklahoma City, RHA owns and operates three critical access hospitals, one medical clinic and an ancillary support services unit, all focused on the delivery of healthcare services to rural communities in Oklahoma. On May 1, 2008, RHA Anadarko, LLC, a wholly owned subsidiary of RHA, purchased 100% of the issued and outstanding membership interests of Southern Plains Medical Center (“ SPMC ”). Founded in 1915, SPMC is one of the oldest continuously operating multi-specialty physician practices in the United States. Located in Chickasha, Oklahoma, SPMC’s 15 physicians and other licensed healthcare providers deliver primary and specialty care in the following areas: family medicine; pediatrics; internal medicine; acute care; occ/med; general surgery; gynecology; ophthalmology; orthopedic surgery; radiology; oncology; cardiology and urology. Ancillary services provided onsite include imaging (computer-assisted tomography (“ CT ”), magnetic resonance imaging (“ MRI ”), mammography, x-ray, EKG, vascular and ultra-sound bone densitometry) and laboratory services. SPMC also provides urgent care services outside of normal business hours seven days a week through its “Quick Care” department. Beginning November 18, 2008, RHA began operating under the trade name Southern Plains Medical Group. On December 11, 2008, we acquired the remaining 49% of the issued and outstanding membership units of RHA, making RHA an indirect wholly-owned subsidiary of ours.

On December 12, 2008, we and certain of our subsidiaries entered into three loan agreements, effective November 6, 2008, with two Oklahoma-based lenders, Bank of Commerce and Valliance Bank, resulting in an aggregate debt financing of $8.4 million. We obtained the financing to purchase the building and real property of the Stroud Regional Medical Center Hospital and clinics, refinance existing loans totaling $4.6 million, upgrade facilities at the Johnston Memorial Hospital and improve the consolidated balance sheet and maintain general working capital. The loans are evidenced by promissory notes issued by RHA Anadarko, LLC, RHA Stroud, LLC and RHA Tishomingo, LLC, two of which mature on November 6, 2028 and one of which matures on November 6, 2024.

On May 1, 2009, we purchased The Chandler Clinic (“ TCC ”), a family medical practice located in Chandler, Oklahoma. TCC is located within the service area of the Stroud Regional Medical Center. As further described in Note 19, “Subsequent Events”, on December 1, 2010, we sold the operations of The Chandler Clinic.

On September 29, 2009, at our Annual Meeting of Stockholders, our stockholders voted to amend our Certificate of Incorporation to change our legal name from “Tri-Isthmus Group, Inc.” to “First Physicians Capital Group, Inc.” to reflect our focus on the healthcare industry. We became First Physicians Capital Group, Inc. on September 29, 2009.

Following the sale of our BPO operations in November 2004, we reduced our headcount significantly to a two-person staff when David Hirschhorn and Todd Parker joined us as our Co-Chief Executive Officers in July 2005. Our new management initiated a growth strategy defined by acquisitions. Our management team and Board of Directors have been and are currently comprised of a group of individuals with complementary talents across a broad range of disciplines, including mergers and acquisitions, finance and operations.

During the Fiscal Years Ended January 31, 2006 and January 31, 2007, our management team focused our acquisition strategy on the healthcare industry.

In December 2006, we resumed active operations following the acquisition of the San Diego ambulatory surgical centers.

In 2007, we refined our acquisition strategy to focus on the delivery of financial and managerial services to healthcare facilities in non-urban markets.

In September 2007, David Hirschhorn became our sole Chief Executive Officer upon Todd Parker’s resignation. Dennis M. Smith, formerly a director and senior consultant to us, re-joined us as our Chief Financial Officer. On October 9, 2008, Mr. Smith’s employment agreement with us was terminated. Effective January 26, 2009, Mr. Smith ceased to be our Chief Financial Officer. Upon the termination of his employment agreement, Mr. Smith had certain contractual rights, pursuant to which we continued to pay Mr. Smith until April 9, 2009. Mr. Smith was offered a severance package to continue his pay beyond April 9, 2009 in recognition for past services rendered, and Mr. Smith accepted the severance package which entitled him to severance payments which began May 10, 2009 and lasted until October 20, 2009. Mr. Smith had and has no disagreements with us on any matter related to our operations, policies or practices. On March 3, 2009, Mr. Smith resigned as a member of our Board of Directors.

In November 2008, we appointed Thomas Rice as President of RHA. Mr. Rice has over 37 years’ experience in the administration and operation of healthcare facilities, including key senior management positions with major Oklahoma-based healthcare services companies. Also in November 2008, we announced the addition of Donald C. Parkerson as Chief Financial Officer of RHA, a position he held until June 2009 when he ceased acting as the CFO of RHA. On January 30, 2009, Mr. Parkerson was also appointed as our Chief Financial Officer. Mr. Parkerson has served in financial leadership positions with companies in healthcare businesses during his more than 30-year career. In November 2008, we hired Richard Rentsch as Vice President of Finance of RHA, and currently he serves as the Chief Accounting Officer of RHA. Mr. Rentsch is an experienced financial leader with more than 25 years of healthcare experience.

Our support staff at RHA’s hospitals and Del Mar consists of registered nurses, operating room technicians, an administrator who supervises the day-to-day activities of the surgery center and a small number of office staff. Each operating unit also has appointed a medical director, who is responsible for and supervises the quality of medical care provided at the center. Use of our surgery centers is limited to licensed physicians. With the acquisition of SPMC in May 2008, we added 15 physicians and other healthcare providers to our team at RHA as employees. Our business depends upon the efforts and success of these physicians and non-employee physicians who provide medical services at our facilities. Our business could be adversely affected by the loss of our relationship with, or a reduction in use of our facilities by, a key physician or group of physicians.

As discussed above, in December 2008, RHA became an indirect wholly-owned subsidiary of ours with the acquisition by RHA of the interests not already held by us.

On January 13, 2010, Southern Plains Medical Center, Inc., our wholly-owned indirect subsidiary and an Oklahoma corporation (“ SPMC ”), entered into a sale/leaseback transaction pursuant to a purchase agreement, whereby SPMC sold certain property to Southern Plains Associates, LLC (“SPA”). SPA is an Oklahoma limited liability company, in which our wholly-owned subsidiary, First Physicians Realty Group, LLC, an Oklahoma limited liability company owns 50% and Capital Investors of Oklahoma, LLC, an Oklahoma limited liability company own the other 50%.

The purchase price for the sale/leaseback transaction was paid to SPMC as follows: (i) $1,500,000 was paid in the form of a promissory note, dated January 13, 2010, and (ii) $4,500,000 was paid in cash at the closing. Our wholly-owned subsidiary, First Physicians Realty Group, LLC, an Oklahoma limited liability company, owns 50% of SPA, and Capital Investors of Oklahoma, LLC, an Oklahoma limited liability company, owns 50% of SPA.

In connection with the purchase agreement, SPMC leased back from SPA the property sold, pursuant to a lease agreement dated December 16, 2009. The lease agreement provides for a 20-year term with an automatic 10-year renewal.

The $4,500,000 in cash proceeds was used to pay off short-term debt associated with the property sold in the amount of $3,700,942, plus related interest. SPMC received net proceeds of $732,221 after retirement of the debt and other associated closing costs. Restricted cash on deposit with the debt holder and pledged as a security on the debt in the amount of $1,524,091 was released and returned to us.

On June 14, 2010, Sean Kirrane was hired as the Vice President of Finance and Controller. Mr. Kirrane has over 10 years experience in senior finance and accounting roles for large publicly traded companies. On August 23, 2010, Mr. Kirrane was appointed to serve as the Company’s Principal Accounting Officer following Mr. Parkerson’s departure.

On August 23, 2010 Donald C. Parkerson resigned his position as Chief Financial Officer, effective this same date. Mr Parkerson’s employment with the Company was governed by an Executive Services Agreement, dated June 27, 2008, by and between the Company and Tatum LLC. Mr. Parkerson had no disagreements with us on any matter related to our operations, policies or practices.

Strategy

Our initial strategy was to identify and invest in “platform” companies in the business services and healthcare industries that provided essential core offerings, which could be expanded over time. As we focused our efforts in the healthcare industry, two particular segments, ambulatory surgical centers and rural hospitals, stood out in terms of fundamentally-favorable economics, positive regulatory trends, inherent cost advantages, improving demographics and, for non-urban healthcare opportunities, a large, under-served market. We determined that the top-down trends and attractive cash flows of ambulatory surgical centers made this an area of particular interest. Less well-known, however, is the non-urban sector, which has suffered from a long-term lack of access to capital despite providing care to more than 50 million people in the United States. We determined that focusing on rural healthcare could represent a significant long-term opportunity for us.

On October 29, 2007, we acquired 51% of the issued and outstanding membership units of RHA. Based in Oklahoma City, RHA owns and operates three critical access hospitals, one medical clinic and an ancillary support services unit, all focused on the delivery of healthcare services to rural communities in Oklahoma. Together, the acquisition of RHA and the subsequent acquisition of SPMC by RHA are referred to herein collectively as the “ RHA Acquisition ,” and the three RHA hospitals, the medical clinic, ancillary support services units and SPMC are referred to herein collectively as the “ RHA Healthcare Operations .” On May 1, 2008, RHA purchased 100% of the issued and outstanding membership interests of SPMC. Beginning November 18, 2008, RHA began operating under the trade name “Southern Plains Medical Group.” On December 11, 2008, through one of our wholly-owned subsidiaries, we acquired the remaining 49% of the issued and outstanding membership units of RHA, making RHA an indirect wholly-owned subsidiary.

Our portfolio was expected to consist of (i) majority interests in healthcare platforms or facilities, such as RHA, the San Diego ambulatory surgical center and SPMC and (ii) equity positions in a diversified portfolio of minority interests in ambulatory surgical centers with a history of positive cash flows. In addition, we expect to selectively invest in business solutions providing financial and processing services to healthcare providers and physicians and in support of new treatment solutions.

In line with our strategy, we re-branded our activities. The operations in the non-urban market previously known as RHA were re-branded “Southern Plains Medical Group” to leverage the old and well-established recognition that SPMC has in the regional markets. In addition, effective September 29, 2009, we changed our name to “First Physicians Capital Group, Inc.” to reflect our focus on the healthcare industry.

In response to local market economic conditions including the expected impact of changes in healthcare law, during the Fiscal Year ended September 30, 2010 we have shifted our strategy and embarked upon initiatives to reorganize our operations. Our strategy has transitioned away from majority ownership in healthcare delivery companies to a focus on healthcare management services and the financing of equipment and real estate used by healthcare entities. We will maintain or acquire minority ownership in selected healthcare delivery companies that complement our management services and financing activities. We will also invest in, acquire or partner with other companies that provide similar services in our markets.

In pursuit of this reorganization, we are divesting underperforming facilities and reducing or outsourcing administrative functions to better align cost structures and business volume.

Funding

We have sustained operating losses since our inception and had an accumulated deficit of approximately $95.5 million as of September 30, 2010, which has been funded primarily through the issuance of preferred stock and common stock, the issuance of promissory notes and cash generated from operations.

As of September 30, 2010 we had current liabilities of $10.3 million and current assets of $6.5 million.

Upon completion of the RHA Acquisition in October 2007, RHA assumed a bank obligation in the amount of $4.4 million (the “ RHA Loan ”). With the completion of the SPMC acquisition by RHA in May 2008, we acquired SPMC bank obligations in the amount of $4.5 million. In December 2008, subsidiaries of RHA obtained three loans totaling an aggregate of $8.4 million, the proceeds of which were used for (i) the purchase of the real property and assets of the hospital operated by RHA in Stroud, Oklahoma for a consideration of $3.2 million pursuant to an existing option agreement; (ii) the repayment of the RHA Loan and (iii) the financing of capital expenditures, fees associated with the financings and working capital requirements (the “ 2008 Loans ”). The 2008 Loans carry amortization schedules of 16-years to 20-years and are guaranteed up to 80% by the U.S. Department of Agriculture Rural Development 80% Business & Industry Loan Guarantee program (“ USDA ”). The completion of the 2008 Loans had the effect of reducing our current liabilities by $4.6 million.

Our recurring losses from operations and anticipated future losses raise substantial doubt about our ability to continue as a going concern. Our plan of operations, even if successful, may not result in cash flow sufficient to finance our business. Realization of our assets is dependent upon our continued operations, which in turn is dependent upon meeting financing requirements and the success of future operations.

Our ability to continue as a going concern is dependent on improving profitability and cash flow and securing additional financing. While we believe in the viability of our strategy to raise additional funds and that the actions presently being taken provide the opportunity to continue as a going concern, there can be no assurances to that effect. These financial statements do not include any adjustments related to the recoverability and classification of asset amounts or the amounts and classification of liabilities that might be necessary if we are unable to continue as a going concern.

2. Summary of Significant Accounting Policies

We prepare our consolidated financial statements in conformity with accounting principles generally accepted in the United States of America. As such, we are required to make certain estimates, judgments and assumptions that we believe are reasonable based upon the information available. These estimates and assumptions affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the periods presented. The significant accounting policies which we believe are the most critical to aid in fully understanding and evaluating our reported financial results include the following:

Principles of Consolidation and Basis of Presentation

The consolidated financial statements include our accounts and the accounts of our subsidiaries. All significant intercompany balances and transactions have been eliminated.

Use of Estimates

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States requires our management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Our actual results could differ from estimates and assumptions made.

Reclassifications

Certain reclassifications and format changes have been made to the prior period amounts in order to conform to the current period presentation.

Cash and Cash Equivalents

Cash consists of cash on hand and amounts deposited with high quality financial institutions. Amounts on deposit at times exceeds the insurance limits. Cash equivalents are highly liquid instruments including cash in money market current accounts that are interest-bearing, capital guaranteed and without any withdrawal restrictions.

Restricted cash consists of funds on deposit with a bank held as security for debt relating to the SPMC acquisition.

Accounts Receivable

Accounts receivable are reported at estimated net realizable amounts from services rendered from federal and state agencies (under the Medicare and Medicaid programs), managed care health plans, commercial insurance companies, workers’ compensation, employers and patients. A significant portion of our revenues are concentrated with federal and state agencies.

Additions to the allowance for doubtful accounts are made by means of the line item “Provision for Doubtful Accounts” in our financial statements. We write off uncollectible accounts against the allowance for doubtful accounts after exhausting collection efforts and adding subsequent recoveries. Net accounts receivable include only those amounts we estimate we will collect.

We perform an analysis of our historical cash collection patterns and consider the impact of any known material events in determining the allowance for doubtful accounts. In performing our analysis, we considered the impact of any adverse changes in general economic conditions, business office operations, payor mix, or trends in federal or state governmental healthcare coverage.

Property and Equipment

Property and equipment are stated at cost. Depreciation for property and equipment is provided using the straight-line method over the estimated useful lives of the respective assets as follows:

Computer hardware			2 to 5 years
Computer software			3 to 5 years
Office equipment, furniture and fixtures			5 years
Medical equipment			5 to 7 years
Buildings			30 to 40 years
Leasehold improvements			15 years

Depreciation for leasehold improvements is provided using the straight-line method over the shorter of the estimated useful lives of the respective assets or the remaining lease term.

Impairment of Goodwill and Long-lived Assets

We review long-lived assets, certain identifiable intangible assets and goodwill related to these assets for impairment. For assets to be held and used, including acquired intangibles, we initiate a review whenever events or changes in circumstances indicate that the carrying value of a long-lived asset may not be recoverable and annually for goodwill and other intangible assets not subject to amortization. Recoverability of an asset is measured by comparison of its carrying value to the future undiscounted cash flows that the asset is expected to generate. Any impairment to be recognized is measured by the amount by which the carrying value exceeds the projected discounted future operating cash flows. Assets to be disposed of and for which management has committed a plan to dispose of the assets, whether through sale or abandonment, are reported at the lower of carrying value or fair value less costs to sell.

In the Fiscal Year Ended September 30, 2010, we determined there was no impairment of Goodwill, however we recorded an impairment of $187,000 of the intangible assets of The Chandler Clinic arising from the sale of the operations on December 1, 2010. See Note 19, “Subsequent Events”, for a discussion of the sale of The Chandler Clinic. In the fiscal year ended September 30, 2009 (the “ Fiscal Year Ended September 30, 2009 ”), we determined that an impairment of the goodwill previously recorded upon the acquisition of RHA had occurred. An impairment charge of $209,000 was recorded.

Revenue Recognition

We recognize revenue when persuasive evidence of an arrangement exists, delivery or performance has occurred, the sales price is fixed or determinable and collectability is probable or reasonably assured.

Income Taxes

The asset and liability approach is used to account for income taxes by recognizing deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. We record a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be realized.

Accounting for Uncertainty in Income Taxes

Financial Accounting Standards Board (“ FASB ”) Accounting Standards Codification (“ ASC ”) 740 creates a single model to address accounting for uncertainty in tax positions by prescribing a minimum recognition threshold a tax position is required to meet before being recognized in the financial statements. FASB ASC 740 also provides guidance on de-recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition. There are no unrecognized tax benefits to disclose in the notes to the consolidated financial statements.

Functional Currency

Our functional currency is United States dollars.

Other Comprehensive Income (Loss)

Other comprehensive income (loss) refers to expenses, gains and losses that under generally accepted accounting principles in the United States are included in comprehensive income (loss) but are excluded from net income (loss), as these amounts are recorded directly as an adjustment to stockholders’ equity, net of tax. Our other comprehensive income (loss) is composed of unrealized gains and losses on foreign currency translation adjustments.

Stock-Based Compensation

Effective February 1, 2006, we adopted the fair value recognition provisions of FASB ASC 718, “Accounting for Compensation Arrangements,” using the modified prospective application method. Our stock option plans are described in Note 14.

Earnings Per Share

Basic earnings/(loss) per share is computed by dividing net income/(loss) by the weighted average shares of Common Stock outstanding during the year. Diluted earnings per share is computed by dividing net income by the weighted average shares of Common Stock and potential common shares outstanding during the year. Potential common shares outstanding consist of dilutive shares issuable upon the conversion of our preferred stock to Common Stock as computed using the if-converted method and the exercise of outstanding options and warrants to purchase Common Stock, computed using the treasury stock method.

Recent Accounting Pronouncements

In December 2007, the FASB issued guidance on “Non-controlling Interests in Consolidated Financial Statements—an amendment of ARB No. 51.” This guidance requires companies with non-controlling interests to disclose such interests clearly as a portion of equity but separate from the parent’s equity. The non-controlling interest’s portion of net income must also be clearly presented on the income statement. This is effective for financial statements issued for fiscal years beginning after December 15, 2008 and was adopted by us in the first quarter of fiscal year 2010. The adoption of the new rules did not have a material impact on our financial condition or results of operation.

In December 2007, the FASB issued updated guidance on business combinations. This guidance applies the acquisition method of accounting for business combinations where the acquirer gains a controlling interest, regardless of whether consideration was exchanged. The updated guidance requires the acquirer to fair value the assets and liabilities of the acquiree and record goodwill on bargain purchases and is effective for financial statements issued for fiscal years beginning after December 15, 2008 and was adopted by us in the first quarter of fiscal year 2010. The adoption did not have a material impact on our financial condition or results of operation.

In January 2010, new guidance was issued regarding improving disclosures about fair value measurements. This standard amends the disclosure guidance with respect to fair value measurements for both interim and annual reporting periods. Specifically, this standard requires new disclosures for significant transfers of assets or liabilities between Level 1 and Level 2 in the fair value hierarchy; separate disclosures for purchases, sales, issuance and settlements of Level 3 fair value items on a gross rather than net, basis; and more robust disclosure of the valuation techniques and inputs used to measure Level 2 and Level 3 assets and liabilities. Except for the detailed disclosures of changes in Level 3 items, which will be effective as of October 1, 2011, the remaining new disclosure requirements are effective as of October 1, 2010.

Fair Value of Financial Instruments

Carrying amounts of certain of our financial instruments, including cash equivalents, accounts receivable and accounts payable approximate fair value due to their short maturities. Carrying value of notes payable and long-term debt approximate fair values as they bear market rates of interest. None of our financial instruments are held for trading purposes.

3. Net Income/(Loss) Allocable to Common Stockholders and Comprehensive Income/(Loss)

The following table is a calculation of net income or loss allocable to common stockholders (in thousands) and comprehensive loss:

		Fiscal				Fiscal
		Year Ended				Year Ended
		September 30, 2010				September 30, 2009
Net loss available to common stockholders		$	(9,544	)		$	(10,368	)
Other comprehensive (loss)/gain foreign currency translations			—				—
Comprehensive income/(loss)		$	(9,544	)		$	(10,368	)

Earnings/(Loss) Per Share

The amounts in the table below are in thousands except for per share amounts.

		Fiscal				Fiscal
		Year Ended				Year Ended
		September 30, 2010				September 30, 2009
Numerator for basic and diluted income/(loss) per share:
Net income/(loss)		$	(9,544	)		$	(10,368	)
Denominator for basic earnings/(loss) per share — weighted average shares			14,819,280				10,977,770
Basic		$	(0. 64	)		$	(0.94	)
Diluted			N/A				N/A

As we had a net loss for the Fiscal Years Ended September 30, 2010 and 2009, potential common shares outstanding are excluded from the computation of diluted net loss per share as their effect is anti-dilutive per standards prescribed in the ASC.

4. Accounts receivable

Accounts receivable consisted of the following:

		September 30,				September 30,
		2010				2009
Gross patient accounts receivable		$	24,911			$	18,470
Reserves for bad debt			(5,648	)			(3,842	)
Reserves for contractual allowances			(15,476	)			(9,737	)
Patient accounts receivable, net		$	3,787			$	4,891

5. Other current assets

		September 30,				September 30,
		2010				2009
Other current assets:
Deposits		$	120			$	120
Medical supplies			500				510
Other receivables			348				1,142
Total other assets		$	968			$	1,772

6. Property and equipment

		September 30,				September 30,
		2010				2009
Property and equipment:
Computer hardware		$	79			$	92
Furniture, fixtures and medical equipment			4,642				4,458
Land			1,029				834
Buildings			14,857				13,340
Construction in progress			—				124
Leasehold improvements			920				944
Accumulated depreciation			(3,970	)			(2,759	)
Property and equipment, net		$	17,557			$	17,033

The gross value of leased capital assets were $7,002,889 at September 30, 2010 and $608,704 at September 30, 2009 which are included in Property and Equipment on the Consolidated Balance Sheet. The accumulated amortization on leased capital assets was $665,960 and $113,012 at September 30, 2010 and September 30, 2009, respectively. Amortization of capital lease assets is recognized over the term of the lease on a straight line basis and included in depreciation expense.

7. Advance to Affiliated Entity

On April 28, 2006, we entered into an agreement with CSA II, LLC, a Cayman Islands company controlled by Dennis M. Smith, one of our former directors. Under the terms of this agreement, we advanced $333,333 to CSA II, LLC to finance the purchase of securities issued by Cross Shore Acquisition Corporation, a Delaware corporation (“ Cross Shore ”), pursuant to a private placement of $112,000,008 of Cross Shore’s securities completed on April 24, 2006. The securities were listed on the Alternative Investment Market of the London Stock Exchange (the “ AIM ”) and started trading on April 28, 2006 and ceased trading on the AIM on September 4, 2009. On August 29, 2007, Cross Shore completed an acquisition by way of a reverse merger with Research Pharmaceutical Services, Inc. (“ RPS ”) and changed its name to RPS as part of the transaction. At September 30, 2007, CSA II, LLC held 167,420 common shares in RPS. In addition, for consideration of $239.38, we purchased warrants to purchase 239,375 membership units of CSA II, LLC, constituting 22.5% of the total issued limited liability company interests outstanding on a fully diluted basis upon payment of the exercise price equal to $0.001 per unit. On May 24, 2006, we received a partial repayment of this advance in the amount of $60,654, leaving a balance of approximately $272,000 at January 31, 2007. On June 12, 2006, we were reimbursed $75,000, representing expenses associated with this advance. In October 2007, approximately $33,000 was reimbursed to us, leaving a balance outstanding of $239,000. Mr. Smith’s interests in RPS represent less than 2% of the issued and outstanding share capital of RPS as of the date of the completion of the reverse merger in August 2007. In light of the disruption in the overall economy at the time, the volatility in the financial markets and restrictions applicable to the sale of RPS common shares by CSA II, LLC, we recorded a charge of $71,635 as a reserve against the repayment of this advance during the Fiscal Year Ended September 30, 2009.

8. Bridge Financing

During the Fiscal Year Ended September 30, 2009, we entered into a bridge financing transaction (the “ Bridge Financing ”) which was consummated in three separate closings. On February 11, 2009, we completed the first closing of the Bridge Financing, a transaction in which we entered into the following two promissory notes, each dated as of February 6, 2009: (i) a convertible promissory note with SMP Investments, LLC, a Michigan limited liability company (“ SMP ”), in the principal amount of $500,000 and (ii) a convertible promissory note with Anthony J. Ciabattoni, Trustee of the Ciabattoni Living Trust, dated August 17, 2000 (“ Ciabattoni ”), in the principal amount of $1,000,000 (collectively, the “ Bridge Notes ”). SMP and Ciabattoni are each a “ Bridge Lender ” and are collectively referred to herein as the “ Bridge Lenders .”

On February 11, 2009, in addition to the issuance of the Bridge Notes, we issued four warrants to purchase Common Stock to the Bridge Lenders as follows: (i) a warrant issued to SMP for the purchase of up to 375,000 shares of Common Stock at an initial exercise price of $0.50 per share and exercisable for a period of three years from the date of issuance; (ii) a warrant issued to SMP for the purchase of up to 250,000 shares of Common Stock at an initial exercise price of $0.75 per share and exercisable for a period of three years from the date of issuance; (iii) a warrant issued to Ciabattoni for the purchase of up to 750,000 shares of Common Stock at an initial exercise price of $0.50 per share and exercisable for a period of three years from the date of issuance and (iv) a warrant issued to Ciabattoni for the purchase of up to 500,000 shares of Common Stock at an initial exercise price of $0.75 per share and exercisable for a period of three years from the date of issuance.

Each Bridge Note originally became due and payable on November 6, 2009; we extended these notes under the terms of an extension option contained in the Bridge Notes. Pursuant to the terms of the extension option, we are required to issue warrants to the Bridge Lenders to purchase shares of Common Stock in the following amounts: (i) to SMP, 125,000 shares at a price of $0.50 per share, and 83,333 shares at a price of $0.75 per share and (ii) to Ciabattoni, 250,000 shares at a price of $0.50 per share, and 166,667 shares at a price of $0.75 per share. The new due date of the Bridge Notes pursuant to the extension option was February 6, 2010; we were to repay the unpaid principal of each Bridge Note on this date, together with accrued and unpaid interest of 16% per annum.

The Bridge Lenders have agreed to extensions as follows: the maturity date of the promissory note held by SMP, in the principal amount of $500,000, is extended to August 6, 2011; the maturity date of the promissory note held by Ciabattoni, in the principal amount of $1,000,000, is extended to February 6, 2013. Effective February 1, 2010, the interest rate was changed from 16% to 10% per annum for the Bridge Notes.

The Bridge Notes include a conversion feature allowing each Bridge Lender to convert all or any portion of the entire unpaid principal and any unpaid accrued interest at the date upon which the conversion is to be effected into a number of shares of Common Stock, determined by dividing the sum of the unpaid principal and unpaid accrued interest at the conversion date by the conversion price in effect at the conversion date. The initial conversion price is $0.625, which price is adjustable as set forth in the Notes. As of September 30, 2010, none of the Bridge Lenders has effected such a conversion.

The Bridge Notes include a provision granting the Bridge Lenders, to the extent that the Bridge Lenders holding notes representing a majority of the aggregate outstanding principal amount of the Bridge Notes agree, demand registration rights with respect to the resale of the shares of Common Stock that would be issuable upon conversion of the Bridge Notes, which rights vest thirty six (36) months after the date of issuance of the Bridge Notes. The registration statement would be prepared by us at our expense and filed on Form S-1 or other appropriate form and, once declared effective, allow the registered securities to be sold on a continuous basis and we will keep the registration statement continuously effective until certain conditions are met which would allow us to stop maintaining its effectiveness.

On March 3, 2009, we completed the second closing of the Bridge Financing, a transaction in which we entered into nine (9) promissory notes, each dated as of March 3, 2009, in the aggregate principal amount of $500,000 (the “ Second Bridge Notes ”), with various investors (the “ Second Bridge Lenders ”).

Each Second Bridge Note originally became due and payable on December 3, 2009, unless the maturity date is extended pursuant to the terms of an extension option. The Second Bridge Notes include a conversion feature allowing each Second Bridge Lender to convert all or any portion of the entire unpaid principal and any unpaid accrued interest at the date upon which the conversion is to be effected into a number of shares of Common Stock, determined by dividing the sum of the unpaid principal and unpaid accrued interest at the conversion date by the conversion price in effect at the conversion date. The initial conversion price is $0.625, which price is adjustable as set forth in the Second Bridge Notes. As of September 30, 2010, none of the Second Bridge Lenders has effected such a conversion.

We extended the Second Bridge Notes for an additional three months under the terms of the extension option contained in the Second Bridge Notes. Upon exercising this option, we were required to issue warrants to the Second Bridge Lenders to purchase an aggregate of 208,333 shares of our Common Stock, 125,000 shares of which will be issued at an exercise price of $0.50 per share and 83,333 shares of which will be issued at an exercise price of $0.75 per share. The new due date for the Second Bridge Notes pursuant to the extension option was March 3, 2010. The Second Bridge Lenders have agreed to an additional extension period for the Second Bridge Notes ranging from eighteen to thirty-six months from the March 3, 2010 due date and also agreed to a reduction in the annual interest rate from 16% to 10%.

The Second Bridge Notes also include a provision granting the Second Bridge Lenders, to the extent holders of a majority of the aggregate outstanding principal amount of the Bridge Notes and Second Bridge Notes agree, demand registration rights with respect to the resale of the shares of Common Stock that would be issuable upon conversion of the Second Bridge Notes, which rights vest thirty-six (36) months after the date of issuance of the Second Bridge Notes. The registration statement would be prepared by us at our expense and filed on Form S-1 or other appropriate form and, once declared effective, allow the registered securities to be sold on a continuous basis and we will keep the registration statement continuously effective until certain conditions are met which would allow us to stop maintaining its effectiveness.

On April 14, 2009, we completed the third closing of the Bridge Financing, a transaction in which we entered into the following three (3) promissory notes: (i) a convertible promissory note, dated as of March 31, 2009, with Frank Darras, Trustee of the Darras Family Trust (“ Darras ”), in the principal amount of $100,000 (the “ Darras Note ”); (ii) a convertible promissory note, dated as of March 31, 2009, with SFV, Inc., a California corporation (“ SFV ”), in the principal amount of $50,000 (the “ SFV Note ”) and (iii) a convertible promissory note, dated as of April 14, 2009, with NFS LLC/FMTC Rol IRA FBO Neal Katz (“ Katz ”), in the principal amount of $50,000 (the “ Katz Note ”) (each, a “ Third Bridge Note ” and collectively, the “ Third Bridge Notes ”). Darras, SFV and Katz are each a “ Third Bridge Lender ” and are collectively referred to herein as the “ Third Bridge Lenders .”

The Darras Note and the SFV Note originally became due and payable on December 31, 2009 and the Katz Note originally became due and payable on January 14, 2010. The terms of each of the Third Bridge Notes contained an extension option to extend such notes for an additional three months at our discretion. We extended the Darras Note and the SFV Note under the terms of the respective options, and therefore are obligated to issue warrants to Darras and SFV as follows: (i) Darras — 25,000 shares at an exercise price of $0.50 per share, and 16,667 shares at an exercise price of $0.75 per share; (ii) SFV — 12,500 shares at an exercise price of $0.50 per share, and 8,333 shares at an exercise price of $0.75 per share. We extended the Katz Note under the terms of an extension option contained in the Katz Note. By exercising this option, we are required to issue warrants to Katz to purchase an aggregate of 20,833 shares, 12,500 shares of which will be issued at an exercise price of $0.50 per share and 8,333 shares of which will be issued at an exercise price of $0.75 per share. The new due dates for the Third Bridge Notes, pursuant to the extension option, were March 31, 2010 for each of the Darras Note and the SFV Note and April 14, 2010 for the Katz Note. The Third Bridge Lenders have agreed to an additional extension period for the notes ranging from eighteen to thirty-six months from the March 31, 2010 and April 14, 2010 due dates and also agreed to a reduction in the annual interest rate from 16% to 10%.

The Third Bridge Notes include a conversion feature allowing each Third Bridge Lender to convert all or any portion of the entire unpaid principal and any unpaid accrued interest at the date upon which the conversion is to be effected into a number of shares of Common Stock, determined by dividing the sum of the unpaid principal and unpaid accrued interest at the conversion date by the conversion price in effect at the conversion date. The initial conversion price is $0.625, which price is adjustable as set forth in the Third Bridge Notes.

The Third Bridge Notes include a provision granting the Third Bridge Lenders, to the extent the holders of a majority of the aggregate outstanding principal amount of the notes issued in the Bridge Financing agree, demand registration rights with respect to the resale of the shares of Common Stock that would be issuable upon conversion of the Third Bridge Notes, which rights vest thirty-six (36) months after the date of issuance of the Third Bridge Notes. The registration statement would be prepared by us at our expense and filed on Form S-1 or other appropriate form and, once declared effective, allow the registered securities to be sold on a continuous basis and we will keep the registration statement continuously effective until certain conditions are met which would allow us to stop maintaining its effectiveness.

The fair value of the warrants issued in conjunction with the convertible notes issued under the Bridge Financing amounted to $932,000, and the fair value of the warrants issued in conjunction with the extension of the Bridge Notes, the Second Bridge Notes, the Darras Note, the SFV Note and the Katz Note amounted to $291,000. The beneficial conversion feature associated with the convertible notes issued in conjunction with the Bridge Financing totaled $253,000. Both the fair value of the warrants issued under the Bridge Financing and the subsequent extension of the Bridge Notes, the Second Bridge Notes the Darras Note, the SFV Note and the Katz Note, as well as the beneficial conversion feature, will be amortized over the term of the loans. Amortization for the Fiscal Years ended September 30, 2010 and 2009 amounted to $522,000 and $952,000, respectively.

Sales of Unregistered Equity Securities

On May 15, 2008, we sold and issued 25 shares of 5-A Preferred to an investor, pursuant to a Series 5-A Preferred Stock and Warrant Purchase Agreement. Such investor represented to us in writing that he was an “accredited investor,” as that term is defined in Rule 501 of Regulation D promulgated under the Securities Act. On May 15, 2008, in connection with this issuance, we also issued warrants to purchase 15,000 shares of our Common Stock to an investor, pursuant to the same Series 5-A Preferred Stock and Warrant Purchase Agreement. These warrants are exercisable for a period of 2 years at an exercise price of $0.50 per share. Such investor represented to us in writing that he was an “accredited investor,” as that term is defined in Rule 501 of Regulation D promulgated under the Securities Act.

In May 2009, we accepted warrant exercises in the amount of 60,000 shares of Common Stock for an aggregate amount of $30,000 from one investor, who represented to us in writing that he is an “accredited investor,” as that term is defined in Rule 501(a) of Regulation D promulgated under the Securities Act. The shares were issued pursuant to the exercise of warrants originally issued on March 23, 2007, in connection with a private placement of our 5-A Preferred to various investors.

In September 2009, we accepted warrant exercises in the amount of 60,000 shares of Common Stock for an aggregate amount of $30,000 from two investors, each of whom represented to us in writing that he is an “accredited investor,” as that term is defined in Rule 501(a) of Regulation D promulgated under the Securities Act. The shares were issued pursuant to the exercise of warrants originally issued on August 10, 2007 and March 8, 2007 in connection with a private placement of our 5-A Preferred to various investors.

On May 21, 2010, we accepted warrant exercises in the amount of 60,000 shares (the “ Warrant Exercise Shares ”) of Common Stock, for an aggregate purchase price of $30,000 from one investor. The Warrant Exercise Shares were issued pursuant to the exercise of a warrant to purchase shares of Common Stock at an exercise price of $0.50 per share, in connection with the private placement of our Series 5-A Preferred Stock and warrants to purchase Common Stock. The investor represented to us in writing that he is an “Accredited Investor,” as that term is defined in Rule 501(a) of Regulation D, promulgated under the Securities Act of 1933, as amended (the “ Securities Act ”). The offers and sales of the Warrant Exercise Shares pursuant to the warrant exercises were exempt from the registration and prospectus delivery requirements of the Securities Act, by virtue of Section 4(2) of the Securities Act and Regulation D promulgated thereunder.

9. Long-term Debt

Long-term debt consists of the following (in thousands):

		September 30, 2010				September 30, 2009
Note payable, secured by equipment, $4,558 payable monthly, including interest equal to the Wall Street Journal Prime Rate, rate is currently 3.25%, through September 2011		$	36			$	89
8% Notes payable to prior shareholders for stock repurchases, five notes outstanding at September 30, 2010, maturity dates ranging from 2013 through 2017			220				260
Note payable, secured by equipment, $2,825 payable monthly, including 13.6% interest through April 2010			—				14
Note payable secured by real estate, $27,513 payable monthly, including interest based on Wall Street Journal prime plus 2% adjusted quarterly, floor of 7%, rate is currently 7%, matures November 2028			3,365				3,453
Note payable secured by real estate, $34,144 payable monthly, including interest based on Wall Street Journal prime plus 2% adjusted quarterly, floor of 7%, rate is currently 7%, matures November 2024			3,348				3,513
Note payable secured by real estate, $9,327 payable monthly, including interest based on Wall Street Journal prime plus 2% adjusted quarterly, floor of 7%, rate is currently 7%, matures November 2028			1,140				1,164

		September 30, 2010				September 30, 2009
Note payable, 5% interest payable quarterly, matures on or before December 11, 2011			1,500				1,500
Capitalized lease obligations — ten leases for buildings and medical equipment with imputed interest rates ranging from 4% to 17.2%, maturing at various dates through 2015			358				521
Note payable, secured by real estate, $36,736 payable monthly, including interest based on Wall Street Journal Prime plus 2% adjusted quarterly, floor of 7%, rate is currently 7%, matures January 2030			4,628				—
Note payable, secured by equipment, $7,530 payable monthly, including 6.75% interest through June 15, 2013			223				298
Note payable, 10% interest, matures on or before April, 2013			2,200				1,416
Note payable, non-interest bearing purchase obligation, annual payments of $83,333, August 2011, $33,333, August 2012 and $33,334, August 2013			150				150
Notes payable, unsecured, 11.25% interest, matures September 2012 through June 2013			1,681				1,027
Note payable, secured by equipment, $1,567 payable monthly, including 6.75% interest through July 2013			48				64
Total			18,897				13,469
Less current maturities of long-term debt			(2,260	)			(1,028	)
Total long-term debt		$	16,637			$	12,441

The following chart shows scheduled principal payments due on long-term debt for the next five years and thereafter:

Fiscal Year Ended September 30,		Payments
2011		$	2,260
2012			3,027
2013			2,361
2014			561
2015			593
Thereafter			10,095
Total		$	18,897

10. Non-controlling Interests

Non-controlling interests attributable to the equity interests in SPA, RHA, Del Mar and Point Loma not held by us and recorded during the Fiscal Years Ended September 30, 2010 and 2009 amounted to $681,000 and $177,000 respectively.

On December 11, 2008, we entered into a Membership Interest Purchase Agreement with RHA, pursuant to which RHA repurchased 49% of the issued and outstanding voting membership units of RHA for an aggregate purchase price of $1,800,000. In connection with the repurchase, RHA issued a promissory note and we entered into a limited guaranty agreement of RHA’s obligations under the promissory note.

During the Fiscal Year Ended September 30, 2009, we entered into a series of equity transactions at Del Mar, which resulted in an increase in non-controlling interests held in Del Mar. Non-controlling interests increased from 39% at September 30, 2008 to 65% at September 30, 2009 and 2010. However, we have a 3:2 voting majority on the board of managers, which gives us control of the management decisions of the center, and Del Mar is still subject to consolidation.

During the Fiscal Year Ended September 30, 2010, SPMC, our indirect wholly-owned subsidiary, entered into a sale/leaseback transaction pursuant to a purchase agreement, whereby SPMC sold certain property to SPA. The purchase price for the sale/leaseback transaction was paid to SPMC as follows: (i) $1,500,000 was paid in the form of a promissory note, dated January 13, 2010, and (ii) $4,500,000 was paid in cash at the closing. Our wholly-owned subsidiary, First Physicians Realty Group, LLC, an Oklahoma limited liability company, owns 50% of SPA, and Capital Investors of Oklahoma, LLC, an Oklahoma limited liability company, owns 50% of SPA. First Physicians Realty Group, LLC has control of SPA and is therefore consolidated into First Physicians Capital Group, Inc.

11. Warrants

Outstanding exercisable warrants consisted of the following as of September 30, 2010:

		Remaining		Exercise
Description		Life		Price				Warrants
September 30, 2007 Preferred Stock Series 5-A warrants issued to investor		1.8 years		$	0.45				50,000
September 30, 2008 warrants issued in connection with notes payable		1 month			0.31				1,980,000
September 30, 2008 warrants issued in connection with notes payable		1 month			0.50				1,237,500
September 30, 2008 Preferred Stock Series 5-A warrants issued to placement agent		2.5 years			0.50				436,250
February 6, 2009 warrants issued in connection with notes payable		1.4 years			0.50				1,125,000
February 6, 2009 warrants issued in connection with notes payable		1.4 years			0.75				750,000
March 3, 2009 warrants issued in connection with notes payable		1.4 years			0.50				375,000
March 3, 2009 warrants issued in connection with notes payable		1.4 years			0.75				250,000
March 16, 2009 warrants issued to advisory board		1.5 years			0.63				83,334
March 31, 2009 warrants issued in connection with notes payable		1.5 years			0.50				112,500
March 31, 2009 warrants issued in connection with notes payable		1.5 years			0.75				75,000
April 14, 2009 warrants issued in connection with notes payable		1.5 years			0.50				37,500
April 14, 2009 warrants issued in connection with notes payable		1.5 years			0.75				25,000
June 8, 2009 Preferred Stock Series 6-A warrants issued to investor		8 months			0.50				210,000
June 10, 2009 warrants issued to Medical Advisory Board		1.7 years			0.63				150,000
October 19, 2009 Preferred Stock Series 5-A warrants issued to investor		1.0 years			0.50				25,800
October 19, 2009 Preferred Stock Series 6-A warrants issued to investor		1.0 years			0.50				4,200
November 6, 2009 warrants issued in connection with notes payable		1.3 years			0.50				375,000
November 6, 2009 warrants issued in connection with notes payable		1.3 years			0.75				250,000
December 3, 2009 warrants issued in connection with notes payable		1.4 years			0.50				125,000
December 3, 2009 warrants issued in connection with notes payable		1.4 years			0.75				83,331
December 2, 2009 warrants issued in connection with issuance of common stock		1.2 years			0.50				60,000
December 14, 2009 Preferred Stock Series 6-A warrants issued to investor		1.2 years			0.50				3,600
December 31, 2009 warrants issued in connection with notes payable		1.5 years			0.50				37,500
December 31, 2009 warrants issued in connection with notes payable		1.5 years			0.75				24,999
January 14, 2010 warrants issued in connection with notes payable		1.3 years			0.50				12,500
January 14, 2010 warrants issued in connection with notes payable		1.3 years			0.75				8,333
									7,907,347

Warrants Issued Pursuant to the Sale and Issuance of Series 5-A Convertible Preferred Stock

During the Fiscal Year Ended September 30, 2008, pursuant to the issuance of 6,085 shares of 5-A Preferred, we issued warrants to purchase an aggregate of 3,651,000 shares of Common Stock to a group of investors. Each investor represented to us in writing that it was an “accredited investor,” as that term is defined in Rule 501 of Regulation D promulgated under the Securities Act. These warrants had an exercise price of $0.50 per share and have expired as of the Fiscal Year ended September 30, 2010. Management is in discussion with the holders of these 5-A Preferred shares about extending the expiration date of the Common Stock warrants (See Footnote 17, “Subsequent Events”).

Warrants Issued Pursuant to the Sale and Issuance of Series 6-A Convertible Preferred Stock

During the Fiscal Year Ended September 30, 2008, pursuant to the sale and issuance of 4,607 shares of 6-A Preferred, we issued warrants to purchase an aggregate of 2,764,200 shares of Common Stock to a group of investors. Each investor represented to us in writing that it was an “accredited investor,” as that term is defined in Rule 501 of Regulation D promulgated under the Securities Act. These warrants had an exercise price of $0.50 per share and have expired as of the Fiscal Year ended September 30, 2010. Management is in discussion with the holders of these 6-A Preferred shares about extending the expiration date of the Common Stock warrants (See Footnote 17, “Subsequent Events”).

During the Fiscal Year Ended September 30, 2009, pursuant to the sale and issuance of 350 shares of 6-A Preferred, we issued warrants to purchase an aggregate of 210,000 shares of Common Stock to an investor. The investor represented to us in writing that he is an “accredited investor,” as that term is defined in Rule 501(a) of Regulation D promulgated under the Securities Act. These warrants have an exercise price of $0.50 per share.

Warrants Issued Pursuant to the Individuals for Advisory Board Participation

During the Fiscal Year Ended September 30, 2008, we issued warrants to purchase 714,285 shares of our Common Stock to Mr. Brian Potiker in consideration for his service on our Advisory Board. These warrants are exercisable for a period of 2 years at an exercise price of $0.45 per share. Mr. Potiker represented to us in writing that he was an “accredited investor,” as that term is defined in Rule 501 of Regulation D promulgated under the Securities Act. These warrants were issued with Black-Scholes assumptions of 101.3% volatility, $0.33 share price, risk-free interest rates of 1.6% and exercise price of $0.45. The warrants had a calculated value of $71,234, recognized over the two-year vesting period. As of September 30, 2008, all of these warrants remained outstanding. These warrants were still outstanding as of September 30, 2009 and were exercised on October 30, 2009.

During the Fiscal Year Ended September 30, 2009, we issued warrants to purchase 125,000 shares of our Common Stock to individuals for participation on our Advisory Board. These warrants were issued with Black-Scholes assumptions of 152% volatility, $0.50 share price, risk-free interest rates of 1.39% and an exercise price of $0.625. The warrants had a calculated value of $50,000, recognized over the two-year vesting period. As of September 30, 2010, all of these warrants remained outstanding.

During the Fiscal Year Ended September 30, 2009, we issued warrants to purchase 150,000 shares of our Common Stock to a member of the newly created Medical Advisory Board. These warrants were issued with Black Scholes assumptions of 152% volatility, $0.52 share price, risk-free interest rates of 2.0% and an exercise price of $0.625. The warrants had a calculated value of $62,000, recognized over the one-year vesting period. As of September 30, 2010, all of these warrants remain outstanding.

Other Warrant Issuances

In connection with the sale and issuance of promissory notes to finance the purchase of RHA on October 29, 2007 during the Fiscal Year Ended September 30, 2008, we issued two groups of warrants to the purchasers of these promissory notes (the “ Holders ”). The first group of warrants, a certain number of which were issued to each of the Holders, allows the Holders to purchase up to an aggregate of 1,980,000 shares of our Common Stock at an initial exercise price of $0.3125 per share, exercisable for a period of three years from the date of issuance. The warrants were issued with Black-Scholes assumptions of 52% volatility, $0.29 share price, risk-free interest rates of 3.13% and exercise price of $0.3125. The warrants had a calculated value of $203,648, recognized over the vesting period. The second group of warrants, a certain number of which were issued to each of the Holders, allows the Holders to purchase up to an aggregate of 1,237,500 shares of our Common Stock at an initial exercise price of $0.50 per share, exercisable for a period of three years from the date of issuance. The warrants were issued with Black-Scholes assumptions of 52% volatility, $0.29 share price, risk-free interest rates of 3.13% and exercise price of $0.50. The warrants had a calculated value of $76,000, to be recognized over the vesting period. Each of the Holders represented to us in writing that it was an “accredited investor,” as that term is defined in Rule 501 of Regulation D promulgated under the Securities Act. As of September 30, 2010, all of these warrants remained outstanding.

During the Fiscal Year Ended September 30, 2008, we issued warrants to purchase 397,250 shares of our Common Stock to Waveland Capital, LLC in connection with their service as placement agent in the private placement of shares of our 5-A Preferred and 6-A Preferred sold and issued during the Fiscal Year Ended September 30, 2008. These warrants are exercisable for a period of 5 years at an exercise price of $0.50 per share. Waveland Capital, LLC represented to us in writing that it is an “accredited investor,” as that term is defined in Rule 501 of Regulation D promulgated under the Securities Act. As of September 30, 2010, all of these warrants remained outstanding. The warrants had a calculated value of $123,000, netted against the proceeds of the above-described private placement.

										Weighted-Average
		Number of Shares of Common Stock								Exercise Price Per Share
		Fiscal				Fiscal				Fiscal				Fiscal
		Year				Year				Year				Year
		Ended				Ended				Ended				Ended
		September 30,				September 30,				September 30,				September 30,
		2010				2009				2010				2009
Warrants outstanding at beginning of the period			14,459,635				11,965,635			$	0.49			$	0.46
Issued			1,010,263				3,235,000			$	0.59			$	0.60
Exercised			(1,105,685	)			(525,000	)		$	0.46			$	0.50
Cancelled or expired			(6,415,200	)			(216,000	)		$	0.50			$	0.48
Warrants outstanding at end of the period			7,949,013				14,459,635			$	0.51			$	0.49

12. Commitments and Contingencies

We lease our operating facilities under non-cancelable operating leases that expire at various dates through 2030. We also lease certain equipment under capital leases. Rent expense was $1.7 million in the Fiscal Year Ended September 30, 2010 and $1.6 million in the Fiscal Year Ended September 30, 2009.

Future minimum lease obligations at September 30, 2010 for those leases having an initial or remaining non-cancelable lease term in excess of one year, are as follows:

		Operating				Capital Lease
Year Ending September 30,		Leases				Obligations				Total
2011		$	1,328			$	192			$	1,520
2012			1,273				123				1,396
2013			789				58				847
2014			436				9				445
2015			324				7				331
2016 and thereafter			75				—				75
		$	4,225			$	389			$	4,614